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  IV 
Zusammenfassung 
 
Viele myxobakterielle Naturstoffe haben strukturelle Besonderheiten und/oder weisen eine neuartige 
biologische Aktivität auf. Im Rahmen dieser Arbeit wurde unter anderem die Biosynthese von 
Ajudazol und Thuggacin in Chondromyces crocatus Cm c5 und von Thuggacin in Sorangium 
cellulosum So ce 895 aufgeklärt. Für die Biosynthese von Ajudazol konnte gezeigt werden, dass die 
Thioesterase (TE) Domäne am Ende des Multienzymkomplexes die Bildung des Isochromanonrings 
unterstützt und auf Grund der katalysierten Reaktion eine neue Klasse von TE Domänen bildet. Des 
Weiteren wurde die Rolle zweier P450 Enzyme, die an der Modifikation des Ajudazolgrundgerüstes 
beteiligt sind nachgewiesen.  
C. crocatus und S. cellulosum produzieren strukturell unterschiedliche Varianten des antimycotischen 
Sekundärstoffes Thuggacin. Durch die Identifizierung, Charakterisierung und dem anschließendem 
Vergleich der beiden Biosynthesewege konnten die entsprechenden enzymatischen Mechanismen, die 
zu den strukturellen Unterschieden führen, aufgeklärt werden. So konnte gezeigt werden, dass im 
S.cellulosum Biosyntheseweg ein zu Crotonyl-CoA-Reduktasen/Carboxylasen homologes Enzym für 
den Einbau der Hexyl-Seitenkette verantwortlich ist. Die unterschiedlichen Hydroxylierungen beruhen 
vermutlich auf der variablen Aktivität einer FMN abhängigen Monooxygenase, deren Funktion in 
C.crocatus nachgewiesen wurde. 
 In weiteren Experimenten wurden die Entstehung der Pyrrolstartereinheit in der Leupyrrinbiosynthese 
in Sorangium cellulsoum So ce690 und die Bildung des Disorazol Dilactons in Sorangium cellulosum 
So ce12 biochemisch untersucht. 
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Abstract 
 
Many myxobacterial natural products display unusual structural features and/or a novel bioactivity, 
making these secondary metabolites attractive targets for study. This thesis describes the elucidation of 
the biosynthetic pathways to the ajudazols and thuggacins in Chondromyces crocatus Cm c5 and the 
thuggacins in Sorangium cellulosum So ce895. Using experiments in vitro and in vivo, we have shown 
that the thioesterase (TE) domain of the ajudazol assembly line “chaperones” the formation of the 
characteristic isochromanone ring, thus placing it within a novel class of TE enzymes. In addition, we 
have demonstrated the involvement of two P450 enzymes in post-assembly line modification of 
ajudazol.  
Distinct variants of the anti-tuberculosis macrolide thuggacins are produced by C. crocatus and 
S.cellulosum. The basis for this architectural diversity has been elucidated by identifying the 
biosynthetic pathways in both myxobacteria, and comparing them in detail. In the course of this 
analysis, a crotonyl-CoA reductase/carboxylase homologue was discovered in the S. cellulosum 
thuggacin gene cluster, and was shown to participate in the assembly of an unusual hexyl side chain. 
Moreover, evidence was provided that the distinct pattern of hydroxylation observed in the C. crocatus 
and S. cellulosum thuggacins may results from variable action of a conserved FMN-dependent 
monooxygenase.  
Finally, we report experiments to probe the formation of the pyrrole starter unit in leupyrrin 
biosynthesis in Sorangium cellulosum So ce690, and the biochemical investigation of the mechanism 
by which the disorazol dilactone structure is generated in Sorangium cellulosum So ce12.  
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Introduction 
 
1.  Natural products in drug discovery 
 
Microorganisms produce an enormous number of secondary metabolites which exhibit a wide 
variety of biological activities useful to man, acting as anti-bacterial, anti-fungal, anti-
parasitic and anti-cancer agents. Furthermore, these molecules are also used in veterinary 
medicine as antibiotics and antiparasitic drugs, and in agriculture as plant growth regulators, 
herbicides and insecticides [1]. In addition to their diverse bioactivities, these so-called ‘natural 
products’ are characterized by a depth of structural diversity which is not available from 
alternative sources. Both of these features explain the continuing dominance of natural 
products as lead structures for the development of novel drugs across many therapeutic areas.  
 
 
Figure 1. Examples of natural products derived from bacteria which are used in the clinic or are in clinical 
trials. The name, natural producing organism and pharmaceutical application are indicated below each 
structure. 
 
In fact, approximately 50% of the pharmaceuticals in clinical use are natural products or their 
derivatives (Examples are presented in Figure 1) [2;3]. Despite this significant success, the 
need for novel natural products for drug development continues. Drivers for drug discovery 
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include the emergence of multi-drug resistance among the latest generation of pathogens, the 
lack of highly effective therapeutics for many diseases, including tuberculosis, and side 
effects associated with some current medicines [1;4]. Although the big pharmaceutical 
companies have largely abandoned their programs in natural product research [5] new natural 
products with unique features are discovered every year by small biotechnology firms and 
academic researchers. 
Among the natural producers of secondary metabolites, besides plants and fungi, 
microorganisms continue to be a promising source for novel metabolites, as only a minor 
proportion of prokaryotic diversity has been examined to date [1]. Efforts have been made to 
identify new groups of microbial producers by analysing bacteria that are difficult to cultivate 
(e.g. cyanobacteria) [6] or are pathogenic (e.g. the genera Nocardia) [7]. In addition, 
underexplored classes of bacteria, such as those from marine environments and the 
myxobacteria [4;8], have come into focus as promising producers of compounds with both 
unique structures and bioactivities. 
 
2.  Myxobacteria – a promising source for novel natural products 
 
Myxobacteria are obligate, aerobic Gram-negative mesophilic δ-proteobacteria which are 
commonly isolated from soil, the bark of trees, decaying plant materials and the dung of 
herbivores [9]. However, the discovery of novel myxobacterial species from moderately 
halophilic soil as well as marine environments, illustrates that they can adapt to a wider 
variety of environmental conditions [10;11]. All known myxobacteria are united in the order 
Myxococcales, which can be further divided into the three suborders Cystobacterineae, 
Sorangiineae and Nannocystineae [12]. More than 7500 strains within the order Myxococcales 
have been already isolated by research groups at the Helmholtz Center for Infection Research 
(Braunschweig, Germany; formerly German Research Center of Biotechnology (GBF)) and 
novel strains, species and even families are continually being discovered [9;13].  
The vegetative cells of myxobacteria are typically rod-shaped and often rather large (4–12 µm 
long and 0.7–1.2 µm wide). When cultivated in liquid media, for most myxobacterial strains 
dispersed growth can be obtained after several passages in specific media except for strains 
from the genera Chondromyces, Polyangium (suborder Sorangiineae) and Nannocystis 
(suborder Nannocystineae). The cells of these genera exhibit a strong tendency to stick 
together, and thus grow preferentially in clumps rather than as independent cells (Figure 2A) 
[14]. On solid surfaces, myxobacteria can glide in coordinated swarms, while under starvation 
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conditions they aggregate to form characteristic multi-cellular structures called fruiting bodies 
(Figure 2B+C) [15]. 
 
 
Figure 2. (A): Cell clumps of Chondromyces crocatus Cm c5 in liquid culture. (B): Swarming behavior of 
Sorangium cellulosum SB So018 on an agar plate. (C): Fruiting bodies of Chondromyces crocatus SB 
Cm010. 
 
The shape and morphology of fruiting bodies can vary highly between different genera, with 
the genus Chondromyces producing the most sophisticated designs [14]. At the end of the 
myxobacterial life cycle, myxospores are formed within the mature fruiting body. These 
structures can withstand environmental extremes, allowing the bacteria to persist for long 
periods in a dormant state [10]. When suitable nutritional and environmental conditions are 
restored, the spores germinate and retransform into viable cells. 
Myxobacteria are also often described as ‘micropredators’, as they are able to feed on other 
living organisms such as other bacteria and yeast [10]. For this, they excrete a variety of lytic 
enzymes that catalyze lysis of the “victim” cells and also subsequently digest the released 
proteins, lipids and nucleic acids. Sorangium cellulosum is particularly notable in this context, 
as it not only feeds on other cells, but it is the sole myxobacterial species that can degrade 
cellulose [14;16]. The predatory and social behaviors of myxobacteria have interested 
microbiologists for decades, but more recently these bacteria have come into focus as multi-
producers of natural products. At least 100 core structures and more than 500 derivatives have 
been identified to date [15], and every year new compounds are discovered [9]. Many of these 
characterized natural products display novel structural features, and modes-of-action which 
tend to differ from those of other secondary metabolites [20-22]. Both attributes make these 
compounds attractive candidates for new lead structures in drug development.  
Prior to genome sequencing, the myxobacterial strains Myxococcus xanthus DK1622 and 
Sorangium cellulosum So ce56 were not known as prominent producers of secondary 
metabolites. However, analysis of their genomes, among the largest yet discovered in 
bacteria, showed that they harbor 18 and 17 secondary metabolite loci, respectively [17;18]. As 
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large genomes appears to be a characteristic of many myxobacteria [17], and there is a strong 
correlation between genome size and the number of secondary metabolite gene clusters in a 
microorganism [19], these findings reinforce the idea that myxobacteria are a promising future 
source of novel natural products.  
 
2.1  Myxobacterial natural products 
 
The first myxobacterial natural product to be applied for clinical use was a semi-synthetic 
epothilone B derivative named Ixabepilone® (Ixempra), which was approved in the United 
States for chemotherapy against breast cancer in 2007 (Figure 3). Epothilone interacts with 
the cytoskeleton of eukaryotic cells by binding to β-tubulin inducing microtubule 
polymerization [23]. The resulting suppression of microtubule dynamics leads to the arrest of 
the cell cycle at the G2/M transition, followed by cell death via apoptosis [24]. As cancer cells 
are highly dependent on microtubule function to support their rapid cell division, the tubulin 
system represents an attractive target for specifically attacking tumor cells [25]. Additional 
myxobacterial compounds that interact with the cytoskeleton include tubulysin and disorazol 
(Figures 3 and 11), which destabilize their tubulin target [26;27] and rhizopodin (Figure 3), 
which binds to actin and prevents its polymerization [28]. All three compounds are potential 
candidates for use in cancer treatment, with several tubulysin derivatives already progressed 
into pre-clinical trials (http://www.innovations-report.de/html/berichte/bildung_wissenschaft/ 
bericht-17016.html). In the case of disorazol a strategy was developed to specifically deliver 
the agent to cancer cells. A variety of cancers, including ovarian, breast and prostate, express 
receptors for luteinizing hormone releasing hormone (LHRH). Thus, in theory, attaching a 
cytotoxic agent to a LHRH peptide agonist provides a means to achieve targeted 
chemotherapy, minimizing potential side effects of these compounds [28b]. Proof-of-principle 
has been demonstrated recently with disorazol, which was shown to induce apoptosis of 
cancer cells following internalization [28b]. 
Another interesting family of myxobacterial natural products are soraphens from Sorangium 
cellulosum (Figure 3). Due to its strong anti-fungal effects, soraphen A was first investigated 
as a plant protective agent [29]. However, development of the metabolite was abandoned when 
the compound’s teratogenic potential was discovered. Nonetheless, these early studies 
revealed important insights into soraphen’s mode-of-action. Soraphen A interacts directly 
with eukaryotic acetyl-CoA carboxylases (ACC) by disrupting the oligomerization of these 
enzymes and thereby inhibiting their activity [30;31]. Notably, acetyl-CoA carboxylases are of 
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critical importance for fatty acid synthesis, as they furnish the central building block malonyl-
CoA. Determining the mode-of-action of soraphen brought the acetyl-CoA carboxylases into 
focus as potential targets in the treatment of both cancer [32] and obesity [33] treatment.  
 
 
 
Figure 3. A selection of myxobacterial secondary metabolites, illustrating both their structural diversity 
and their varied biological activities. The compound name and mode-of-action are given below each 
structure.  
 
The two myxobacterial strains Sorangium cellulosum So ce895 and Chondromyces crocatus 
Cm c5, both produce structural variants of the novel antibacterial macrolide thuggacin 
(Figure 10). Thuggacins have been shown to effectively inhibit the bacterial respiratory chain 
in several Gram-positive bacteria, including clinical isolates of Mycobacterium tuberculosis, 
the causative agent of tuberculosis (TB) [34;35]. This bioactivity is particular promising as it 
represents an alternative mode of action compared to the current first- and second-line 
antibiotics in TB treatment which mainly interact with RNA, DNA and cell wall synthesis. 
The bacterial respiratory chain is a particularly promising target for new chemotherapeutics, 
as it appears to be essential for both replicating and non-replicating mycobacteria [36]. 
Other targets of myxobacterial secondary metabolites include the mitochondrial electron 
transport chain (e. g. myxothiazol, melithiazol) [37;38], eubacterial RNA polymerases (e. g. 
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myxopyronin/corralopyronin, sorangicin )[39-41] and protein synthesis (e. g. myxovalargin) [42] 
(Figure 3).   
Despite the diversity of structures, the majority of known myxobacterial secondary 
metabolites are linear or cyclic polyketides (PKs) and non-ribosomal polypeptides (NRPs), 
which are constructed by a common biosynthetic logic. In fact, more than 50% of identified 
compounds contain both PK and NRP elements, and therefore are termed hybrid PK-NRP 
metabolites [20]. In contrast, such mixed natural products are quite rare in other bacterial 
secondary metabolite producers such as the actinomycetes, which synthesize preferentially 
pure PK or NRP compounds [20].  
3.  Polyketide and nonribosomal peptide biochemistry 
 
PK and NRP natural products are assembled on multienzymes called polyketide synthases 
(PKS), and nonribosomal peptide synthetases (NRPS), respectively [43;44]. PKSs, NRPSs and 
their hybrids, are large multifunctional enzyme complexes that utilize monomeric building 
blocks such as short acyl-CoA esters and amino acids to build molecules of high complexity 
[45;46]. The mode of operation of these multienzymes is often described as an assembly line, as 
they display a modular organization in which each module is responsible for the incorporation 
of one building block into the growing product chain [47;48]. In addition, each module can be 
further subdivided into domains, which represent the enzymatic units that are responsible for 
the individual steps of loading, condensation and subsequent (though optional) modification 
of a specific extender unit.  
The genes encoding the biosynthetic machineries are typically clustered together in the 
microbial genomes, and are often co-localized with transcriptional regulators and genes for 
self-resistance [49]. In some cases, there is a one-to-one correspondence between the domains 
present in the PKS/NRPS and the set of biosynthetic transformations which occurs, an 
observation referred to as ‘colinearity’ [50]. Based on this colinear principle, modules and 
domains that are involved in the biosynthesis of a particular natural product can be predicted 
by analyzing the structure of the compound. This ‘retrobiosynthetic analysis’ approach can 
significantly enable the search for the corresponding gene cluster. Conversely, if the cluster is 
already identified but its product is unknown, the organization of the assembly line can be 
used to predict some aspects of the metabolite’s basic backbone structure. 
The operation of PKS and NRPS systems is also described as a ‘multiple carrier thio-template 
mechanism’ [51;52]. The central feature of this model is that during the assembly process, all 
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substrates, intermediates and products remain covalently tethered via a thioester-linkage to a 
carrier protein (CP) domain within a chain-extension module. 
 
Figure 4. Post-translational modification of a CP domain by a PPTase. The PPTase catalyzes the transfer 
of phosphopantetheine from coenzyme A to a conserved serine in the CP domain, converting the inactive 
apo CP to the active holo form. 
 
Therefore, in order to produce a functional enzymatic assembly line, each CP has to be post-
translationally modified by a phosphopantetheinyltransferase (PPTase) enzyme. PPTases are 
specialized, discrete enzymes that act in trans to transfer the 4`-phosphopantetheine (Ppant) 
moiety of CoA to conserved serine residues of the CPs, converting the domains from their 
inactive apo to their active holo forms (Figure 4) [46;53]. During the biosynthesis, the 
intermediates are bound as thioesters to the terminal thiol group of this phosphopantetheine 
arm, which activates the substrates for Claisen or amide bound condensation. In addition, the 
covalent linkage between substrate and the phosphopantetheine arm allows the intermediates 
to be shepherded between the individual active sites, without diffusing into the cellular 
medium. This sequestration provides an effective means to stabilize the reactive 
intermediates, as well as a kinetic advantage to the overall biosynthesis. 
3.1 PKS biochemistry  
 
The biosynthesis of a polyketide backbone requires three essential core domains, an 
acyltransferase (AT), a ketosynthase (KS) and an acyl carrier protein (ACP).The AT domain 
selects the specific extender unit, the KS domain catalyzes the condensation between the 
extender unit and the growing chain, and the ACP is responsible for delivering the 
intermediate to the various catalytic domains. A typical PKS module contains all three 
domains, with the exception of initiation modules, which can be organized in two different 
ways. One type of starter module contains all three core domains. However, the KS domain of 
this initiation module is catalytically inactive for condensation as its active site cysteine has 
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been replaced by a glutamine (this type of KS is therefore referred to as a KSQ domain). As 
the starter module typically provides a monocarboxylic acid for the first elongation step, the 
KSQ domain catalyzes decarboxylation of the (methyl)malonyl-S-ACP to generate the 
required building block (e.g. propionate/acetate). The second type of loading module is a 
didomain, consisting of an AT and an ACP. In this case, the AT domain directly selects short 
chain monocarboxylic acids such as acetyl- and propionyl-CoA as starter units. In addition, 
certain initiation modules recruit less common building blocks, such as aromatic and 
branched-chain carboxylic acids [54-57]. In either case, however, the starter unit is ultimately 
delivered to the KS domain of the first chain extension module.  
In chain extension modules, AT domains typically exhibit a preference for dicarboxylic acids 
such as malonyl-CoA and methylmalonyl-CoA. In some cases, however, uncommon extender 
units are recognized, such as hydroxymalonyl-ACP, methoxymalonyl-ACP and 
aminomalonyl-ACP [58-61]. The corresponding substrates are selected by the AT domain while 
they are attached to the ACP, and are then transferred to a carrier protein within the 
multienzyme. Sequences analysis of numerous AT domains has revealed conserved amino 
acids motifs which can be correlated to substrate specificity [62-64]. The prediction of substrate 
specificity based on these conserved residues is relatively reliable, but in some cases, the 
identified code cannot be related with confidence to a certain extender unit, which can be 
regularly observed in myxobacterial systems [56;57;65].  
After selection of a specific extender unit, the AT domain transfers it to the Ppant moiety of 
the ACP domain within its own module. The ACP-bound extender unit is then decarboxylated 
and the resulting enolate attacks the upstream KS-bound acyl thioester. This KS-catalyzed 
condensation results in a β-keto-acyl-ACP intermediate which is extended by one C2 unit, and 
which is covalently bound to the ACP domain of the extension module (Figure 5A). At this 
stage, the intermediate can be transferred to the KS domain of the following module and 
participate in another chain elongation step (Figure 5A).  
The structural diversity of PKs can be enhanced by the action of modifying domains, which 
are optionally present in certain modules and act directly after the chain elongation step [50;66]. 
Depending on whether ketoreductase (KR), dehydratase (DH) and enoylreductase (ER) 
domains are incorporated in a particular module, various extents of redox adjustment of the β-
keto functionality can result. Initially the KR domain catalyzes the stereospecific and 
NADPH-dependent reduction of the β-keto function to the β-hydroxy intermediate. 
Subsequently the DH carries out dehydration, leading to an α,β-enoyl intermediate, which can 
ultimately be reduced to the fully saturated acyl chain by the ER domain, with further 
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consumption of NADPH (Figure 5B). A full ‘reductive loop’, i.e. all three enzymatic 
domains acting in tandem, is not necessarily present in every PKS module [50]. Consequently 
the partial or full omission of the sequential ketoreduction, dehydration and enoyl reduction 
reactions during polyketide assembly in a 
 
 
 
Figure 5. Schematic overview of PKS biochemistry. (A): AT domains from module 1 (initiation module) 
and module 2 (first elongation module) select their respective acyl-CoA monomers (1) and catalyze the 
transthiolation of these substrates to the downstream ACP domains (2). In the next step, the intermediate 
from module 1 is transferred to the KS of module 2 (3). Subsequently decarboxylative condensation 
catalyzed by the KS domain occurs to form the C–C bond between the upstream acyl thioester and the 
downstream enolate (4+5) R1= CH3 or a less common starter unit (see text) R2 = H, CH3. (B): Optional β-
carbon processing catalyzed by the KR, DH and ER domains. R = remaining polyketide chain. Domains 
that are involved in a specific catalytic step are colored in grey.  
 
highly programmed manner is one of the biosynthetic features underlying the structural 
diversity of PK products. 
Recent protein sequence analysis of KR domains led to the identification of several conserved 
motifs that allow the stereochemistry (‘A’- or ‘B-type’) of the resulting hydroxyl moiety to be 
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predicted [67;68]. If the KR is followed by a DH domain a correlation between B-type 
ketoreduction and the formation of a trans double bond by syn dehydration and for A-type 
ketoreduction and the formation of a cis double bond by the same mechanism could be 
observed [67;68]. Of course, as for all in silico predictions, this correlation is not absolute [69]. 
Furthermore, the final stereochemistry of saturated, methyl branched sites can be predicted 
from a distinct specificity motif within the ER domains [70]. With these recent discoveries, it is 
now possible to predict the absolute configuration of a product from the gene sequences. 
The termination module is the last module of the assembly line and is responsible for the 
release of the full-length acyl chain. This process of chain termination is typically catalyzed 
by a thioesterase (TE) domain, whose function is described in more detail in section 3.4. 
 
As an aside, it’s worth mentioning that in addition to type I modular PKSs, two other types of 
PKS systems are known in nature. Type II systems consist of a set of discrete and usually 
monofunctional enzymes that form a multienzyme complex, and are used iteratively to 
produce polycyclic, aromatic metabolites [66]. In type III systems, the catalytic activity of a 
single active site accomplishes the complete biosynthesis, which includes decarboxylation, 
condensation, cyclization and aromatization reactions [71;72]. Another fundamental difference 
between type III systems and the others, is that they use CoA-esters instead of ACP bound 
intermediates as substrates.  
3.2 NRPS biochemistry 
 
By analogy to PKS biosynthetic logic, a minimal NRPS module also consists of three core 
domains: adenylation (A), condensation (C) and peptidyl carrier protein (PCP). NRP 
biosynthesis is initiated by an A domain, which selects a specific amino acid (Figure 6A). 
The specificity of A domains is not restricted to the 20 proteinogenic amino acids, as they can 
also recognize and activate a much wider variety of nonproteinogenic amino and aryl acids as 
monomer building blocks [46]. This biosynthetic feature contributes to the high structural 
diversity within this class of natural compounds.  
The crystal structure of PheA from gramicidin S synthetase [73] coupled with analysis of 
primary sequences from various A domains, led to the identification of 8–10 amino acids 
residues within the substrate binding pocket that constitute the major determinants of A 
domain substrate specificity [73-75]. This ‘nonribosomal code’ is a useful tool to predict the 
substrate specificity of an A domain, even if the natural product is unknown. However, it is 
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not possible to make a confident specificity prediction for all A domains, as in some cases the 
extracted code cannot be assigned to a certain amino acid.  
 
 
 
Figure 6. Schematic overview of NRPS biochemistry. (A): Selection and activation of a specific amino acid 
by the A domain. ATP is consumed in the activation reaction (1), and the aminoacyl group of the obtained 
aminoacyl-AMP is transferred to the PCP domain (2). (B): The C domain catalyzes a condensation 
reaction (3) which results in formation of a peptide bond between two adjacent aminoacyl-S-PCP 
intermediates. Catalytic domains involved in a particular reaction are indicated in grey. 
 
In addition to its function in selecting a specific residue, each A domain also activates the 
amino acid to its aminoacyl-adenylate by consuming ATP (Figure 6A). In the next step, the 
amino acid is transferred to the peptidyl carrier protein (PCP) domain. The subsequent 
condensation reaction between amino acyl substrates tethered to PCPs of adjacent modules is 
catalyzed by the condensation (C) domain. The amino group of the downstream aminoacyl-S-
PCP performs a nucleophilic attack on the acyl group of the upstream peptidyl-S-PCP, leading 
to the generation of a new peptide bound (Figure 6B). As a result, the peptide intermediate is 
elongated by one amino acid and remains covalently linked to the PCP of the downstream 
module. Additional elongation steps can follow until the end of the assembly line is reached. 
As with PKS machinery, NRPS modules can also contain optional domains that increase the 
structural variety of the final products. A notable example is a variant of the C domain, the 
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heterocyclization (HC) domain. In addition to peptide bond formation, this domain catalyzes 
the heterocyclization of functional side chains of the amino acids cysteine, serine and 
threonine with the peptide backbone. The obtained five-membered hydrolytically labile 
thiazoline or oxazoline rings can be further oxidized to stable thiazol or oxazole heterocycles 
by oxidation (Ox) domains using FMN as cofactor.  
 
 
Figure 7. Reactions of various modifying catalytic domains. (A): Formation of an oxazole ring catalyzed 
by HC and Ox domains. After catalyzing the condensation between two aminoacyl intermediates, the HC 
domain facilitates the attack of an internal nucleophilic (in this case, a serine) on the adjacent carbonyl, 
followed by dehydration to yield the oxazoline. Subsequently an Ox domain can act on the oxazoline 
using FMN as hydrogen acceptor, converting it to the fully-reduced aromatic oxazole. (B): N-methylation 
catalysed by an N-MT domain. The methylation of the aminoacyl-S-PCP amine occurs prior to the 
condensation, and requires S-adenosylmethionine (SAM) as co-factor. (C): E-domain catalyzed 
epimerization occurs after amide bond formation. Domains that participate in a specific reaction are 
shaded in grey.   
 
Ox domains have been reported frequently in modules that already contain a HC domain, and 
can be integrated into the corresponding A domain (Figure 7A) or located downstream of the 
module’s integral PCP [53]. Many NRPS also contain methyltransferase (MT) domains which 
are responsible for N- or C- methylation of amino acids residues, modifications which prevent 
premature proteolytic breakdown of the peptides [53]. MT domains transfer the methyl group 
from S-adenosylmethionine (SAM) to the amino group or carbon of the respective aminoacyl-
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S-PCP intermediate, before the condensation with the upstream peptidyl-S-PCP occurs 
(Figure 7B). Furthermore, some NP products contain D-amino acids, which is notable as D- 
amino acids only occur rarely in the microbial producers. Three different mechanisms have 
been discovered for how NRPSs can generate D-amino acids and integrate them into their 
product structures. The simplest way is to use a D-amino acid-selective A domain, as for 
example in cyclosporine biosynthesis [76]. Here, the required D-amino acid is generated by an 
external racemase [77]. Alternatively, a subtype of C domain as observed in arthrofactin 
biosynthesis displays dual activities, catalyzing both condensation and epimerization of L-
amino acids [78]. However, the most common method involves epimerization of a PCP-
tethered L-amino acid, catalyzed by an epimerization (E) domain which is integrated into the 
respective module. This catalytic domain acts in cis on aminoacyl-S-PCP and peptidyl-S-PCP 
intermediates during initiation and elongation, respectively (Figure 7C).  
When the last module is reached, the final peptide chain is typically transferred to a TE 
domain, and released from the assembly line (see also section 3.4).   
3.3 PKS-NRPS hybrids 
 
Hybrid PK-NRP natural products are derived from both amino acids and carboxylic acids. 
The corresponding biosynthetic machineries can be divided into two classes according to the 
mechanisms by which the different building blocks are incorporated into the final product 
[79;80]. The first class does not involve functional interactions between NRPS and PKS 
modules. Consequently the peptide and polyketide moieties are synthesized independently 
and are coupled afterwards by a discrete enzyme, as for example in coronatine biosynthesis 
[81-83]. The second class, which includes most of the myxobacterial hybrid products, involves a 
functional interaction between NRPS and PKS modules, i.e. a PKS-bound growing ketide 
chain is directly elongated by a NRPS module or vice versa. The functionality of mixed 
systems depends on several events. First, a PPTase with broad substrate specificity for both 
ACPs and PCPs is needed to convert both types of CP domains into their active forms. Most 
of the PPTases analyzed to date, including EntD and ACPS from E. coli, show high 
specificity towards a certain type of CP [84]. But with the biochemical characterization of Sfp, 
Svp and the myxobacterial MtaA, three PPTases have been discovered that efficiently 4`-
phosphopantetheinylate both ACPs and PCPs, as required for the functioning of hybrid PKS-
NRPS systems [85-87]. 
Another point to be considered is the transfer of intermediates across NRPS-PKS and PKS-
NRPS interfaces, respectively. At a PKS-NRPS interface, the C domain must condense a 
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ketide chain on an upstream ACP domain with an amino acid extender unit tethered to the 
downstream PCP. In contrast, at NRPS-PKS interfaces, the KS domain must first accept an 
upstream peptidyl intermediate for transacylation onto its own active site, and subsequently 
catalyze the condensation reaction with a downstream acyl-S-ACP. Consequently ACP/PCP 
and C/KS are the critical domains for the functional interaction in hybrid PKS/NRPS systems. 
They have to recognize and cooperate with domains from the other type of system on the one 
side and on the other side they also have to accept and catalyze the corresponding substrates. 
Obviously, intermodular communication in hybrid systems is essential for the transfer of the 
growing chain over the mixed interfaces. This process is also facilitated by sequence regions 
that either physically join the PKS and NRPS modules together within subunits (‘linkers’), or 
allow them to interact non-covalently (‘docking domains’) across intersubunit junctions. 
3.4  Type I and Type II TEs: chain release and proof-reading 
 
In most cases, the last module of both PKS and NRPS assembly lines contains a C-terminal 
type I thioesterase (TE) domain which is responsible for release of the full-length product. 
Here, the intermediate is transacylated from the Ppant arm of the final carrier protein onto the 
active site serine of the terminal TE domain. The TE domain then catalyzes the controlled off-
loading of the product (Figure 9A). One mode of chain release is hydrolysis, in which the 
final intermediate is transferred to water as external nucleophile. Hydrolysis is the fate, for 
example, in the release of the myxobacterial metabolites spirangien and DKxanthene by their 
respective assembly lines [92;93]. Alternatively, and more frequently, the TE catalyzes an 
intramolecular nucleophilic attack of a suitable internal nucleophile (e.g., -OH or -NH2) on 
the product chain, releasing a macrocyclic compound [94]. A large variety of products can 
result from this reaction, based on the nature of the acyl chain (polyketide, polypeptide or 
hybrid), the location of the nucleophile which is used for the cyclization (to generate simple 
rings or more complex branched structures [95]), and the type of linkage. For example, if an 
internal hydroxyl is used to close the ring, the result is a macrolactone such as in the 
polyketide erythromycin A [96]. Alternatively, the selection of an amine as internal nucleophile 
can result in an intramolecular peptide bond, as in the polyketide vicenistatin [97]. 
Furthermore, macrocycles can be also formed by the cyclooligomerization of several 
intermediate chains, as in the case of gramicidin S [98], enterobactin [99] and disorazol [100]. In 
the case of gramicidin S, a ten-membered ring is formed by the head-to-tail joining of two 
identical pentapeptidyl units [98]. The ability of TEs to catalyse a variety of chain release 
reactions also raises the interest in their potential as useful biocatalysts. It could be shown, 
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that NRPS TE domains expressed as stand-alone proteins efficiently catalyze 
macrocyclization of linear peptides, which vary significantly in structure from their native 
substrates [101-103]. Considering the large number of TE domains found to date, these enzymes 
might find utility in future in the synthesis and diversification of cyclic peptides and 
polyketides. 
  
 
 
Figure 9. Role of type I and type II TE domains in natural product synthesis. (A): Transfer of the final acyl 
chain from the phosphopantetheinyl arm of the last ACP onto the active site serine of the type I TE 
domain (1). Depending on the character of the TE, the acyl-enzyme intermediate can undergo hydrolysis 
and be released as free acid or experience intramolecular cyclization to form a macrocyclic product. (B): 
Aberrant decarboxylation of the chain extender unit catalyzed by the KS domain. The resulting acyl group 
(e.g. acetate or propionate) is attached to the ACP and blocks the assembly line. The discrete type II TE 
catalyzes hydrolytic release of the acyl chain, restoring the activity of the ACP domain. (C): Removal of a 
wrongly attached amino acid from the PCP by TE II. (D): Erroneous modification of a PCP with an acyl-
CoA derivative due to the relaxed selectivity of the PPTase. To regenerate the inactive NRPS, the TE II 
hydrolyzes the thioester and leaves only the 4′-phosphopantetheine cofactor on the PCP. Domains 
involved in a particular process are colored in grey. 
 
In addition, some biosynthetic gene clusters also contain a second TE domain. These discrete 
type II TEs are not absolutely essential for secondary metabolite production by the modular 
megasynthases, as various disruption experiments on type II TEs resulted in a significant 
decrease but not in complete abolishment of product yields [104-106]. It was therefore postulated 
that type II TEs improve the efficiency of product formation by their associated NRPS/PKS 
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systems by regenerating blocked assembly lines. In PKS systems, ACPs can be stalled by 
short fatty acyl thioesters that are derived by aberrant KS-catalyzed decarboxylation of the 
chain extender units in the absence of an appropriate acceptor chain. The TEII would 
thereupon interact with the incorrectly acylated ACP by transferring the corresponding acyl 
group to its active site serine (Figure 9B). The regenerated ACP is then able to continue its 
normal operations, while the TEII releases the acyl group via hydrolysis [107].  
In NRPS systems, TEIIs are assumed to recover the activity of blocked NRPS modules in two 
ways. During the conversion from apo to holo NRPS, the PPTase may transfer an acyl-4`-
phosphopantetheine moiety instead of a 4′-phosphopantetheine group onto a PCP. This 
mistake would lead to a misprimed NRPS that is inactive, as one of its 4′-PPant arms is 
blocked by an acyl group. It has been shown that TEIIs can regenerate misprimed NRPS by 
hydrolyzing these short chain acyl CoA-groups (Figure 9D) [108]. It seems likely that 
malfunctioning PPTases could also cause blockages in PKS systems, but this mechanism has 
not yet been directly demonstrated. Additionally, type II TEs in NRPS systems can also 
restore the activity of modules that are blocked with unprocessed aminoacyl intermediates. 
These incorrectly loaded amino acids are recognized by the TEII and consequently released 
by hydrolysis from the corresponding PCP (Figure 9C) [108;109]. In mixed PKS-NRPS 
systems, type II TEs are required to be more promiscuous, as they have to recognize 
misprimed ACPs as well as PCPs, and the corresponding aberrant intermediates [110].  
 
3.5  Post-assembly line modifications 
 
After release from the multienzyme complex, many secondary metabolites are chemically 
modified by discrete enzymes which are also encoded in the biosynthetic gene clusters [111;112]. 
These modifications modulate the physicochemical properties such as hydrophobicity and/or 
binding properties of the released product scaffold, and are often responsible for conferring 
bioactivity on the natural products. In actinomycetes, PKs are often decorated with additional 
moieties such as sugars, hydroxyls and methyl groups [50;113]. In contrast, NRP products are 
typically modified during assembly of their scaffold by cis acting domains (see part 3.2). 
Nevertheless glycosylations and oxidative cross-linking by trans acting enzymes, have been 
observed in NRPS systems [111].  
Post-assembly line modifications, particularly glycosylations, are quite rare in myxobacteria 
[20;21]. Only a few glycosylated myxobacterial compounds have been identified to date, among 
them chivosazol and sorangicin [41;114]. In addition, halogenation reactions which are quite 
common for natural products from marine microbes are also rather unusual in myxobacterial 
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compounds [8]. However, two halogenases involved in the biosynthesis of two different 
myxobacterial natural products were described recently. One of these enzymes chlorinates the 
2-position of a tryptophan residue in the chondramides, and therefore represents an example 
of a rare tryptophan 2-halogenase [115]. The second halogenase was discovered in the 
chondrochloren gene cluster and is FAD-dependent. The natural substrate of this halogenase 
could not be identified yet. However it was assumed that it accepts carrier-bound substrates 
[116]. Furthermore, hydroxylations, methylations and acylations of myxobacterial natural 
products have been observed [44]. 
Enzymes which are involved in post-assembly line modifications have been also targeted for 
their potential as biocatalysts [117]. They often display novel reaction mechanisms, which can 
be potentially used for the synthesis and derivatization of pharmaceutical compounds and 
drug intermediates [117]. For example studies of glycosyltransferases were carried out to define 
their biocatalytic potential [118;119]. In addition experiments with P450 enzymes showed that 
these enzymes are able to hydroxylate next to their native PKS substrates also non-native 
substrates and are consequently good candidates for bio-engineering [120].  
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4.  Outline of this work 
 
The overall goal of the work described in this thesis was to carry out studies on the 
biosynthesis of several myxobacterial secondary metabolites and consequently increase our 
knowledge about both modular assembly lines and post-assembly line modifications. Specific 
aims included a comparative analysis of thuggacin biosynthesis in Chondromyces crocatus 
Cm c5 and Sorangium cellulosum So ce895, and studying several aspects of the assembly of 
three other metabolites, ajudazol (Chondromyces crocatus Cm c5), disorazol (Sorangium 
cellulosum So ce12) and leupyrrin (Sorangium cellulosum So ce690).  
 
The thuggacins (Figure 10) are macrolide antibiotics which were identified recently from the 
myxobacterial strains Chondromyces crocatus Cm c5 and Sorangium cellulosum So ce895 
[34;35]. The most striking structural difference between the set of compounds in each strain is 
the branching functionality at carbon C2. C. crocatus Cm c5 thuggacins (Cmc-thuggacins) 
incorporate a methyl moiety at this position whereas the S. cellulosum So ce895 thuggacins 
(Soce-thuggacins) contain an uncommon hexyl side chain. The only other known secondary 
metabolite with such a hexyl-branching is cinnabaramide from the Streptomyces strain JS360 
[121]. In addition, the pattern of modification by hydroxylation also differs between the strains. 
Soce-thuggacins incorporate a hydroxyl group at carbon C20 which is not present in the Cmc 
compounds, while in contrast, the C32 hydroxyl moiety of the Cmc thuggacins is absent in the 
Soce counterparts. Ring-size variants are found in both strains, but these derivatives likely 
arise from spontaneous rearrangement during the isolation process and are thus not 
biologically relevant [35]. Interestingly, the ring configuration does not appear to influence the 
compounds’ bioactivity, as Soce-thuggacins A and B are equally active [35]. In addition to 
these notable structural features, the thuggacins show promising biological activity. The 
compounds were found to inhibit the respiratory chain in several Gram-positive bacteria, 
including clinical isolates of Mycobacterium tuberculosis, the causative agent of tuberculosis 
(TB) [34;35]. As TB remains the second most lethal infectious disease worldwide and drug-
resistant TB strains are increasingly emerging, the demand for novel therapeutics has 
increased [122]. Chemotherapeutics such as the thuggacins which target the bacterial 
respiratory chain are of particular interest, as they also affect dormant bacteria [123]. As the 
thuggacin gene clusters had not been identified in either strain, the first goal was to locate the 
biosynthetic loci by screening the appropriate cosmid libraries, coupled with gene inactivation 
experiments in C. crocatus Cm c5 and S. cellulosum So ce895 to prove the cluster identities. 
For C. crocatus Cm c5, a cosmid library was already available [115] and methods for genetic 
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modifications were established, whereas for S. cellulosum So ce895, the project required both 
generating a cosmid library and developing methods for genetic manipulation of the strain. 
 
 
Figure 10. Structures of the thuggacins produced by Sorangium cellulosum So ce895 and Chondromyces 
crocatus Cm c5. (A) Thuggacins derived from S. cellulosum So ce895:  Soce-thuggacin A (1), Soce-
thuggacin B (2), Soce-thuggacin C (3), and the minor metabolite 13-methyl-thuggacin A (4). Compounds 2 
and 3 are derived from spontaneous rearrangement of 1. (B) Thuggacins isolated from C. crocatus Cm c5:  
Cmc-thuggacin A (5) and Cmc-thuggacin C (6). 6 is derived from 5 during isolation.  
 
Once the clusters were identified, sequenced and annotated, both biosynthetic machineries 
were compared in detail to elucidate the origin of the structural variations in the metabolites 
derived from both strains. For this, post PKS/NRPS genes that were putatively involved in 
this process were inactivated in the appropriate strain, and where possible, the corresponding 
recombinant proteins were analyzed in vitro via an appropriate biochemical assay. As the 
thuggacin yields in C. crocatus Cm c5 are quite low, an additional aim was to increase 
production by inserting a strong constitutive promoter directly in front of the biosynthetic 
gene cluster by homologous recombination. The obtained data and their analysis are reported 
in Chapter 3, 4 and 7.   
 
The antifungal ajudazols A and B (Figure 11) are potent inhibitors of mitochondrial electron 
transport, and were also isolated from the natural product multi-producer C. crocatus Cm c5 
[124;125]. Ajudazols are novel isochromanone derivatives which incorporate an extended 
side chain containing a heterocyclic oxazole ring, a Z,Z-diene and a 3-methoxybutenoic acid 
amide. Ajudazol A, the major metabolite, contains an exo-methylene functionality at carbon 
C-15 instead of the methyl group found in ajudazol B. The aim of this project was to annotate 
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the corresponding gene cluster, which was initially identified by Dr. Shwan Rachid, and to 
use this information to develop a detailed biosynthetic hypothesis. Furthermore, the roles of 
two cytochrome P450-encoding genes involved in post-assembly line modifications were 
investigated. For this, the genes in C. crocatus Cm c5 were inactivated, and the structures of 
the resulting products were analysed by HPLC-MS and NMR, in order to determine the 
function of the enzymes. The results of this study are presented in Chapter 1. 
 
 
 
Figure 11. Structures of ajudazol A and B produced by Chondromyces crocatus Cm c5, leupyrrin A1 from 
Sorangium cellulosum So ce690 and disorazol A1 derived from Sorangium cellulosum So ce12.  
 
Another goal of the ajudazol project was to investigate the formation of the isochromanone 
ring. The isochromanone ring system is quite uncommon for a modular type I PKS, as 
biosynthesis of aromatic structures by bacteria is typically accomplished by type II or type III 
PKS systems. Other rare examples for bacterial type I PKS products with aromatic moieties 
are stigmatellin and lasalocid. In the stigmatellin pathway a novel cyclization domain which is 
located at the C-terminal end of the assembly line appears to catalyze cyclization and 
aromatization to yield the final chromone ring [126]. The mode of formation of the benzenoid 
ring in lasalocid biosynthesis remains unknown, although the bacterial type I PKS 
incorporates a typical type I TE domain [127]. Therefore the question emerged how the 
isochromanone ring system is formed by the ajudazol PKS-NRPS, which terminates in a TE 
domain. The role of the ajudazol TE in the ring formation process was investigated using 
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experiments both in vitro and in vivo. The obtained data and their analysis are reported in 
Chapter 2.   
 
In addition, the role of the C-terminal TE domain in disorazol biosynthesis was investigated. 
Disorazol (Figure 10) consists of two nearly identical monomers that are fused together at the 
end of the assembly line to form the characteristic dilactone core structure [100]. The aim of 
this project was to express the TE domain heterologously and to examine in vitro its function 
in macrodiolide formation. The results of this project are summarized in Chapter 5.  
 
The final project targeted the leupyrrin family of compounds, which were isolated from 
several Sorangium cellulosum strains [128]. Leupyrrins are an elegant example of the extent of 
structural variety within myxobacterial compounds (Figure 10): in addition to PK and NRP 
building blocks, the molecules also incorporate an isoprenoid unit as well as a dicarboxylic 
acid [129]. The majority of the biosynthetic gene cluster responsible for leupyrrin assembly had 
already been identified by Maren Kopp [130]. Therefore, as follow-up work, in vitro studies 
were performed to investigate a specific step in the biosynthesis, the generation of the starter 
unit pyrrole carboxylic acid. This study is presented in Chapter 6. 
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Introduction 
The bioactivity of several myxobacterial natural products is based on their interaction with the 
cytoskeleton of cells from higher organisms. Compounds with this mode-of-action are of 
particular interest in the pharmaceutical industry, as they can potentially be applied in cancer 
therapy. Disorazol, which is produced by the myxobacterial strain Sorangium cellulosum So 
ce12, inhibits the polymerization of tubulin and induces apoptosis at picomolar concentrations 
[131]. The disorazol family of metabolites consists of 29 derivatives that on the basis of their 
structural characteristics, can be sub-divided into 7 structural groups and 3 additional 
metabolites [132]. All disorazols are macrocyclic dilactones of a 4-oxazolecarboxylic acid that 
is linked with a C15 chain in position 4, except for disorazol Z which incorporates a shorter, 
C13 chain. The diversity of the disorazol family arises by variable modification of this chain, 
including altering the configuration and location of double bonds, and the presence or absence 
of epoxide, hydroxyl and methoxyl functionalities. In addition, ring-expanded disorazols have 
been observed [132].  
 
 
Figure 1. Schematic representation of disorazol biosynthesis in Sorangium cellulosum So ce12. The 
modules are used iteratively to generate the final product. Shaded in grey are the two ester linkages that 
are formed during dimerization of the two intermediate chains (scheme according to Kopp et al. [100]).  
 
Recently the hybrid PKS/NRPS gene cluster responsible for disorazol biosynthesis was 
identified, and the pathway was partially elucidated [100;133]. The assembly line incorporates 10 
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PKS and one NRPS module, although three of the PKS modules (module 8, 10 and 11) are 
proposed to be inactive as their KS domains lack a conserved active site histidine. AT 
domains are uniformly missing from the PKS modules, and instead, the extender unit 
malonyl-CoA is provided to the ACP domains by the discrete trans acting AT domain 
encoded on disD. Thus the disorazol PKS-NRPS is a ‘trans AT’ system. Furthermore, 
analysis of the catalytic domains in modules 1–7 led to the assumption that these modules are 
responsible for the formation of one monomer of the disorazol dilactone (Figure 1). 
Following module 7, the chain-extension intermediate is probably directly transferred to the 
NRPS module (module 9) and the inactive module 8 is skipped. After the incorporation of the 
amino acid serine, the necessary chain length is reached. However, the NRPS module is 
followed by two additional PKS modules. To account for this organization, it has been 
proposed that these modules do not catalyze chain extension, but instead pass the intermediate 
along until the C-terminal TE domain is reached [133].  
As the disorazol biosynthetic machinery only contains the number of modules required for 
biosynthesis of one monomer within the bislactone, it is likely that the modules are used twice 
to generate the final product. Consequently, the TE domain is likely to be involved in the 
dimerization of two monomeric chains to yield the final macrodiolide structure. However, to 
attempt to demonstrate directly this function of the disorazol TE, the domain was expressed 
heterologously and in vitro studies were performed with a substrate which mimicked one 
simplified monomer of the disorazol Z molecule, derivatized as its N-acetylcysteamine (NAC) 
thioester (Figure 2B).  
 
Experimental procedures 
Cloning of pET28bDisTE 
Disorazol TE was PCR amplified from BAC D17 [100] using the primers DisTEfwdI (5′-
tgagcCATATGagcaacggcgcagcccggca-3′) and DisTErev (5′-acctgGCGGCCGCtcatgaaagcg 
cctcgcggacgtg-3′). The forward primer contained an introduced NdeI restriction site while the 
reverse primer was designed to include a NotI site downstream of the stop codon (restriction 
sites are shown in bold and underlined). The PCR product was cloned into pJET1.2 
(Fermentas), digested with NdeI and NotI, and subsequently ligated into the expression vector 
pET-28b+ (Novagen), previously digested with NdeI and NotI. The obtained expression 
construct was designated as pET28b-DisTE and verified by sequencing. 
Heterologous expression and purification of DisTE 
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The expression construct pET28b-DisTE was transformed into the strain E. coli Rosetta BL21 
(DE3)pLysS/RARE (Novagen). Expression was carried out in LB medium (200 mL) 
containing kanamycin sulfate (40 µg mL-1) and chloramphenicol (20 µg mL-1) at 37 °C. 
Protein expression was induced at A600 = 0.8–1.0 by addition of isopropylthio-β-D-
galactosidase (IPTG) to a final concentration of 0.2 mM. After induction, the cells were 
cultivated at 16 °C over night. Cells were then harvested by centrifugation at 15344 g at 4 °C. 
Purification of the protein was carried out at 4 °C using an ÄktaPrime Purification System 
(GE Healthcare). The cell pellet was resuspended in buffer A (20 mM Tris (pH 7.8), 200 mM 
NaCl, 10% glycerol, 10 mM imidazole; 20 mL). The cells were broken by three passes 
through a French Press (1000 psi) and the insoluble material was sedimented from the lysate 
by centrifugation at 15344 g at 4 °C. The lysate was filtered through a 1.2 µm syringe filter 
(PALL®), before being applied to a HisTrap™ HP column (1 mL; GE Healthcare). All steps 
of the purification were carried out at a flow rate of 1 mL min-1. The protein extract (20 mL) 
was loaded onto the column after an equilibration step with buffer A (20 mL). After loading, 
the column was washed with buffer A (20 mL), and then the proteins were eluted using a 
stepwise gradient with buffer B (buffer A + 500 mM imidazole) to give concentrations of 60, 
100, 200, 300 and 500 mM imidazole. Elution of the proteins was monitored by recording the 
absorbance at 280 nm. Appropriate fractions were analyzed by SDS-PAGE. The fractions 
containing the recombinant protein were pooled, concentrated with an Amicon Ultra-4 
concentrator (10 kDa cut-off; Millipore) and desalted using a PD-10 column (GE Healthcare) 
into storage buffer (50 mM Tris-HCl (pH 7.6), 1 mM EDTA, 10% glycerol, 2 mM DTT). 
Purified protein was then flash frozen in liquid nitrogen and stored at –80 °C. Typically, 1.7 
mg of purified protein was obtained from 200 mL cell culture. 
Enzyme assay 
The reaction mixture (120 µL) contained buffer (50 mM Tris (pH 8.0), 150 mM NaCl), 5 µg 
NAC thioester (synthesized by R. Schäckel and M. Kalesse, University of Hannover.) and 
0.75 µg purified DisTE. The assay was incubated overnight at 30 °C and quenched by the 
addition of 120 µL MeOH. After centrifugation, the supernatant was dried by evaporation and 
then redissolved in 100 µL MeOH. Finally, the sample was analyzed using high resolution 
mass spectrometry. High-resolution measurements were performed on an Accela UPLC-
system (Thermo-Fisher) coupled to an LTQ-Orbitrap (linear trap-FT-Orbitrap combination) 
operating in positive ionization mode. Compounds were separated on a BEH RP-C18 column 
(Waters; 50  2 mm, 1.7 µm particle size, flow 0.6 mL min-1), using a solvent system 
consisting of water and acetonitrile, both containing 0.1% formic acid. The following gradient 
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was applied: 5–95% acetonitrile over 9 min. The UPLC-system was coupled to the Orbitrap 
by a Triversa Nanomate (Advion), a chip-based nano-ESI interface.  
Results  
In order to demonstrate the role of DisTE in the dimerization process, we aimed to evaluate 
the activity of the domain towards a synthetic NAC thioester which mimics one monomer of 
the dilactone. The expression construct for DisTE was designed to incorporate the majority of 
the linker between the TE and the upstream ACP domain (starting 5 amino acids C-terminal 
to the ACP). This strategy had already proven successful for the expression of the terminal TE 
domain from the erythromycin PKS, which is also located downstream of an ACP domain 
[134]. The gene was cloned into the vector pET28b+ in order to obtain a N-terminally His6-
tagged protein, and expression was carried out in E. coli RosettaTM BL21(DE3)pLysS/RARE 
cells. Recombinant DisTE was then purified by affinity chromatography (Figure 2A), and the 
identity of the protein was confirmed by MALDI-MS analysis.  
 
 
 
Figure 2. (A): SDS-PAGE analysis of the DisTE domain (calculated molecular weight: 37.2 kDa). The left 
lane contains molecular weight marker. (B): NAC thioester used in this study.  
 
 
The available NAC-ester (provided by collaboration partners Romy Schäckel and Markus 
Kalesse, University of Hannover) represents a simplified monomer of the natural product 
disorazol Z (Figure 2B). For each assay, the TE (0.75 µg) was incubated with the linear 
NAC-monoester (5 µg) in assay buffer, and analysis of the reaction products was carried 
using HPLC-MS (Figure 3). The major compound that was detected had an accurate mass of 
m/z [M+H]+ = 348.18072 (retention time (r.t.) = 5.7 min). This mass is consistent with the 
molecular formula C19H25NO5 (calc’d. [M+H]+ = 348.18055, Δ = 0.5 ppm), which 
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corresponds to the hydrolytic product of the NAC-monoester, i.e. the free acid of the model 
substrate. In addition, minor amounts of two compounds with the accurate mass of m/z 
[M+H]+ = 778.37424 (r.t. = 7.7–7.8 min) were detected.  
 
 
Figure 3. High resolution HPLC-MS analysis of products formed by DisTE. ( (A): Extracted ion 
chromatogram EIC of m/z [M+H]+ = 348.180. A compound (r.t. 5.7 min) with a mass consistent 
with the hydrolytic product of the NAC-monoester (structure 1) (calculated m/z [M+H]+ for 
C19H25NO5 = 348.18055; found: 348.18072; Δ = 0.5 ppm) was detected. (B): EIC of m/z [M+H]+ = 
778.374. Two compounds (r.t.= 7.7–7.8 min) corresponding to the mass of linear dimer tethered 
to the NAC moiety (most likely structures 2 and 2') (calculated m/z [M+H]+ for C42H56N3O9S = 
778.37318; found: 778.37424; Δ = 1.363 ppm) were detected. (C): EIC of m/z [M+H]+ = 659.333. 
Four compounds (r.t.= 7.7–8.7 min) having a mass consistent with the cyclic dimer (structures 
3, 3', 3'' and 3''') (calculated m/z [M+H]+ for C38H46N2O8 = 659.33269; found: 659.33301; Δ = 0.5 
ppm) were detected. The alternative esters that can be formed depending on the hydroxyl 
group used are shown in grey.  
  
The corresponding sum formula C42H56N3O9S (calc’d. [M+H]+ = 778.37318, Δ = 1.363 ppm) 
is consistent with a linear dimer of the substrate tethered on one end to the NAC (linear 
dimeric NAC-thioester). Formation of two linear dimeric NAC-thioesters (2 and 2′) likely 
occurs by alternative use of the two nucleophilic hydroxyl moieties (C4 or C6; linear 
monoester numbering) during installation of the ester bond.  
Furthermore, several compounds (r.t. = 7.7–8.7 min) with an accurate mass of m/z [M+H]+ = 
659.33301 were identified. The predicted sum formula for these compounds, C38H46N2O8, 
(calc’d. [M+H]+ = 659.33269, Δ = 0.5 ppm) tallies with the cyclic dilactone structure. These 
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structures likely correspond to dilactones of varying size, whose formation again depends on 
the particular hydroxyl moiety used to create the ester linkage (Figure 3). As further evidence 
for the role of the DisTE in generating these products, none of the compounds were formed in 
a negative control containing boiled DisTE (data not shown). The comparison of the 
integrated peak areas from the different products resulted in following approximate ratios: 
free acid to linear dimer 4.5:1 and free acid to cyclic products 1.5:1.  
 
Discussion 
Several non-ribosomal peptide natural products consist of dimerized or trimerized monomeric 
chains, including gramicidin S [98] and enterobactin [99]. In addition such structures can also be 
generated by hybrid PKS-NRPS machineries, as for example in rhizopodin biosynthesis ([135] 
and D. Pistorius, unpublished). The monomeric chains are produced by iterative use of the 
assembly line, while the cyclo-oligomerization is catalyzed by the TE domain at the C-
terminal end of the biosynthetic machinery [136]. Consequently, in these systems, TE domains 
are of particular interest as they are somehow able to ‘count’ the appropropiate number of 
linked monomers, before releasing the final product by intramolecular cyclization. 
This iterative mode of biosynthesis has been demonstrated directly for the gramicidin (GrsB) 
and enterobactin (EntF) TEs, which produce dimerized and trimerized products, respectively 
[136;137]. After the first chain is transferred to the TE, the TE selects a nucleophilic residue in 
the substrate tethered to the upstream PCP, and uses it to attack the acyl terminus of the chain 
bound at its active site serine. This step yields a linear dimer attached to the PCP domain. The 
dimeric intermediate is then transferred to the TE, at which point the TE either catalyzes 
intramolecular cyclization/release, or forms a trimeric species in cooperation with the 
upstream PCP, before releasing the final product [136;137]. By constructing molecules in this 
way the ‘economic’ advantage for the bacterium is obvious. Instead of using a very large 
assembly line that generates the natural product in one run, a shorter and energetically cheaper 
biosynthetic machinery is used several times in series to generate one molecule. However this 
system requires the evolution of a specialized TE capable of catalyzing the required reactions. 
The mixed PKS-NRPS system for disorazol biosynthesis also appears to use this mechanism, 
as the natural product consists of a cyclic dimer of two almost identical monomeric chains, 
although the corresponding gene cluster only contains the number of modules appropriate to 
generate chains with the length of one monomer. The structural differences between the 
monomeric chains in the final molecule are postulated not to be generated during the 
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assembly of the natural product on the biosynthetic machinery but after the release of the core 
molecule by post assembly line modifications. 
To show directly that DisTE has a similar function as GrsBTE and EntFTE, the domain was 
expressed heterologously and tested for its ability to form the dimeric cyclic product with a 
NAC-thioester mimicking one half of the disorazol Z molecule. A simplified version of the 
disorazol Z monomer was chosen as it represents the disorazol with the shortest C-chain and 
is therefore easier to synthesize. The major product of this experiment was the free acid of the 
linear monomeric NAC-thioester, which likely arose from DisTE-catalyzed hydrolysis. 
However, cyclic dimeric products as well as linear dimeric NAC-thioesters were also detected 
in minor amounts, whereas the ratio between free acid and cyclic dimeric products is 
approximately 1.5:1 and the ratio between free acid and linear dimeric products is 4.5:1. The 
cyclic derivatives with identical masses likely correspond to differently-sized macrodiolide 
rings, as each monomeric-NAC-thioester has two free hydroxyl groups (C2 and C6) that can 
potentially participate in ester bond formation (Figure 3). Indeed, variously-sized 
macrodiolide rings, representing all possible combinations of ester linkages between the free 
hydroxyl groups were also observed among the 29 natural disorazol derivatives, i.e. ester 
bonds are formed between either the outer or inner hydroxyl groups but also all mixed 
possibilities (outer and inner hydroxyl group are linked with each other via an ester bond) 
could be detected [132]. In addition, alternative use of hydroxyl nucleophiles also likely 
accounts for formation of the two different linear dimeric NAC-thioesters. Based on the 
obtained data, it appears that in general the DisTE shows relatively broad specificity towards 
the different nucleophiles in the in vitro assay. These findings are supported by the various-
sized disorazols produced in vivo. However, a certain preference of the DisTE for ester bond 
formation between the two inner hydroxyl groups can be assumed as the major natural 
product is disorazol A1 (Figure 1) [132]. 
Characterization of the excised tyrocidine TE domain also yielded a similar ratio of hydrolytic 
versus cyclized products [103]. In contrast, when such an iteratively-acting TE was expressed 
as a fusion protein with the corresponding upstream PCP, as for GrsB PCP-TE, the amount of 
hydrolytic product decreased relative to the yields of linear dimerization and cyclic products 
[137]. In our assay, the monomeric NAC-thioester, a mimic of the acyl-CP, is provided in trans, 
as in the study with the tyrocidine domain. In the first encounter between NAC-thioester and 
DisTE, the intermediate chain is transferred from the NAC onto the TE domain. To generate 
the dimeric cyclic product, a second monomeric chain has to be presented to the DisTE. 
However, in contrast to the cis-acting PCP-TE systems in which the required monomer is 
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assembled on the adjacent PCP domain, performing the reaction in trans with discrete species, 
means that the second monomer will have to reach the TE active site by diffusion. Evidently, 
the diffusive delivery of the second NAC-thioester is too slow to guarantee an efficient 
encounter in time between the intermediate-tethered TE and the second monomeric NAC-
thioester. Consequently the intermediate bound to DisTE is more likely to be released by 
hydrolysis than to dimerize with the second NAC-thioester. Taken together, our results show 
that it is essential for a successful dimerization process that the TE domain already loaded 
with one substrate chain is directly supplied with the second chain by an upstream CP 
domain, a result consistent with the earlier literature [136]. 
A linear dimer of gramicidin – the product corresponding to the linear dimeric NAC 
thioesters seen with DisTE – was observed during characterization of GrsB using a 
monomeric pentapeptidyl-SNAC as substrate [137]. The product only retains its NAC-
functionality when the DisTE catalyzes ester bond formation between one of the two free 
hydroxyl moieties of a linear NAC monoester and the acyl terminus of the TE-bound 
monomer. If the reaction were to occur in the opposite manner, that is by attack of a free 
hydroxyl group of the TE tethered monomer onto the acyl terminus of the NAC-monomer, 
followed by hydrolysis, the products would be linear dimers of the free acids (e.g. NAC-free). 
As such products were not observed in these experiments, the DisTE must catalyze cyclo-
oligomerization by the conventional mechanism. 
 
 
Figure 4.  Proposed mechanism for the formation of disorazol. First, one of the two hydroxyl groups from 
the CP-tethered acyl-chain nucleophilically attacks the acyl terminus of the intermediate bound to the TE 
domain. In the second step, the CP-bound dimer is transferred to the active site serine of the TE, which 
than catalyzes the cyclization reaction, with concomitant release of the final product.  
 
By analogy with the results obtained with GrsB [137], we propose the following overall 
mechanism for the linkage and cyclization of two monomeric chains by DisTE: initially one 
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monomeric chain is transferred onto the active site serine of DisTE from the adjacent CP. In 
the next step, one of the two hydroxyl groups of a second upstream CP-tethered monomer is 
used to form an ester bond with the acyl terminus of the TE-bound monomer, resulting in a 
dimer covalently linked to the CP domain. Subsequently the dimer is transferred to the active 
site serine of the TE, which than catalyzes the cyclization reaction to generate the final 
bislactone product (Figure 4).  
In the disorazol assembly line, several CP domains are possible candidates for involvement in 
the formation of the cyclic dimer. As the last building block is incorporated by module 9, it is 
possible that the PCP domain present in this module directly interacts with DisTE. On the 
other hand, both ACPs of the non-elongating modules 10 and 11 contain the active site serine 
necessary for the domains to be functional [133]. Therefore, an alternative possibility is that the 
intermediate is handed off to these modules, and ultimately the ACP domain from module 11 
and the adjacent TE cooperate to catalyze the three steps of cyclodimerization. In fact, the 
latter mechanism seems more likely, as ACP11 and the TE domain are covalently linked to 
each other, which should facilitate a significantly more efficient interaction. 
 
 
 
Figure 4.  Sequence alignment of the linker region between ACP and TE of different PKS/NRPS hybrid 
systems (tubulysin, ajudazol, disorazol) and one PKS system (spirangien). The vertical bars mark the end 
of the ACPs and the start of the TEs. 
 
In addition, the linker region between ACP11 and the TE domain is exceptionally long 
compared to other myxobacterial ACP-TE junctions (Figure 5). A similar observation was 
made for GrsBTE, and it was speculated that the extended linker region may be important for 
the mobility of the TE [137]. Indeed, a high degree of mobility is necessary as the enzyme has 
to access the multiple substrate positions on the CP-bound intermediate chains.  
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Introduction 
The antifungal leupyrrins are produced by several myxobacterial strains, including Sorangium 
cellulosum So ce690 [138]. Extensive feeding studies revealed that the leupyrrins consists of a 
PK as well as a NRP portion, but also incorporate an isoprenoid unit and a dicarboxylic acid 
[129]. One amino acid that is integrated into the leupyrrin scaffold is L-proline which forms the 
pyrrole moiety representing the starter unit of leupyrrin biosynthesis. Pyrrole moieties derived 
from L-proline are found in a number of structurally diverse natural products, including 
coumermycin A1 [139] and Dkxanthene [93]. The mechanism for the conversion of the 
pyrrolidine ring of L-proline to a pyrrole has been elucidated for the biosynthesis of 
clorobiocin, undecylprodigiosin, but also several other biosynthetic pathways [140-143].  
 
 
Figure 1. Schematic representation of pyrrolyl-2-carboxyl-S-PCP synthesis as shown for clorobiocin, 
coumerycin A1, and undecylprodigiosin biosynthesis. 
 
Typically in these systems three distinct enzymes work together. First an A domain 
recognizes and activates L-proline and subsequently transfers it to a stand-alone PCP domain 
to generate the L-prolyl-S-PCP intermediate. The subsequent desaturation reactions to 
generate the pyrrolyl-2-carboxyl-S-PCP are carried out by a FMN-dependent dehydrogenase 
[140;141]. The pyrrole can then be transferred to the adjacent polyketide synthase for further 
biosynthetic steps (Figure 1). Based on this precedent, we hypothesized that the leupyrrin 
pyrrole moiety would be formed by an analogous mechanism. Therefore, the recently 
identified gene cluster was searched for possible candidate genes encoding the required set of 
enzymes [130]. Indeed, this analysis revealed a stand-alone A domain (leu5) and a 
dehydrogenase homologue (leu6). For the CP domain, two alternative candidates were found: 
a discrete ACP domain encoded on leu7 and a didomain consisting of C and a PCP domain 
(leu9) which also did not play an obvious, alternative role in the biosynthesis (Figure 2). In 
fact, Blast analysis shows that the discrete ACP (and the A and dehydrogenase domains) are 
most similar to those from the anatoxin system, suggesting that the ACP was most likely 
involved in the generation of the pyrrol-unit [143]. However as the nonribosomal code of the A 
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domain was not unambiguous [130] we aimed to characterize the substrate specificity of the A 
domain in vitro.  
 
 
 
 
 
 
Figure 2.  Portion of the leupyrrin gene cluster. Shaded in grey are the proteins that are possibly involved 
in the formation of the starter unit pyrrolyl-2-carboxyl-S-CP. 
 
Experimental procedures 
Cloning of pET28bleuorf5 
The gene encoding orf5 was PCR amplified from the cosmid C9. The primers used for the 
amplification were Leuorf5fwd (5′-gacacGCGGCCGCctactcgccccgttcaagc-3′) and 
Leuorf5rev (5′-ctgctCATATGacgtacctgttgcatcagc-3′) containing the introduced restriction 
sites NotI and NdeI. PCR was carried out with Phusion polymerase (95°C 15 s; 67°C 20s; 
72°C 30s; 30 cycles). The PCR product was cloned into pJET1.2 (Fermentas), digested with 
NdeI and NotI, and subsequently ligated into the expression vector pET-28b+ (Novagen), 
previously digested with NdeI and NotI. The obtained expression construct was designated as 
pET28bleuorf5 and was verified by sequencing.  
Expression and purification of Leuorf5 
Expression of pET28bleu5 was carried out in E. coli Rosetta BL21 (DE3)pLysS/RARE 
(Novagen). The cells were grown at 37 °C to an OD600 of 0.8–1 in 200 ml LB media 
supplemented with kanamycin (40 µg ml-1) and chloramphenicol (20 µg ml ml-1). Expression 
of orf5 was induced by addition of IPTG to a final concentration of 0.2 mM. Cells were 
harvested after overnight cultivation at 16 °C by centrifugation (15344 g, , 5 min, 4 °C). The 
cell pellet was resuspended in buffer A (20 mM tris(hydroxylmethyl)aminomethane (Tris)-
HCl (pH 7.8), 200 mM NaCl, 10 mM imidazole, 10% glycerol) and lysed by three passes 
through a French press (1000 psi). Cell debris was removed by centrifugation (15344 rpm, 45 
min, 4 °C). The lysate was filtered through a 1.2 µm syringe filter (PALL®), before being 
applied to a HisTrap™ HP column (1 mL; GE Healthcare). Purification of Leuorf5 was 
carried out with the Äkta Prime system at 4 °C and a flow rate of 1 mL min-1. After 
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equilibration of the column with buffer A (20 mL), the protein extract was loaded onto the 
column. The column was then washed with buffer A (20 mL), and the proteins were eluted 
using a stepwise gradient with buffer B (buffer A + 500 mM imidazole) to give 
concentrations of 60, 100, 200, 300 and 500 mM imidazole. Elution of the proteins was 
monitored by recording the absorbance at 280 nm. Appropriate fractions were analyzed by 
SDS-PAGE. The fractions containing the recombinant protein were pooled, concentrated with 
an Amicon Ultra-4 concentrator (10 kDa cut-off; Millipore) and desalted using a PD-10 
column (GE Healthcare) into storage buffer (50 mM Tris-HCl (pH 7.6), 1 mM EDTA, 10% 
glycerol, 2 mM DTT). A second purification step was carried out with the Äkta Prime using 
anion exchange chromatography. For this, a 1 mL HiTrapQ HP column (GE Healthcare) was 
utilized at a constant flow rate (1 mL min-1). The pre-purified protein sample (3.5 mL) was 
loaded onto the column after an equilibration step with buffer C (50 mM Tris-HCl (pH 7.6), 1 
mM EDTA, 10% glycerol, 2 mM DTT). After loading (15 mL), the column was washed with 
buffer C (5 mL) followed by elution of the proteins using a linear gradient with buffer D 
(buffer C + 1 M NaCl; 0–1 M NaCl over 25 mL). 2 mL fractions were collected and elution of 
the proteins was monitored by recording the absorbance at 280 nm. Appropriate fractions 
were analyzed by SDS-PAGE and fractions containing the recombinant protein were pooled, 
concentrated with an Amicon Ultra-4 concentrator (10 kDa cut-off; Millipore) and desalted 
using a PD-10 column (GE Healthcare) into storage buffer (50 mM Tris (pH 7.5), 50 mM 
NaCl, 1mM DTT, 10% glycerol). Leuorf5 was then flash-frozen in liquid nitrogen and stored 
at –80°C. The protein concentration was determined using the Bradford assay (Bio-Rad), and 
the identity of the protein was confirmed by MALDI. 
ATP-[32P]PPi exchange assay for aminoacyl-AMP formation 
Reactions (100µL) for determining substrate specificity contained 75 mM Tris-HCl (pH 8.0), 
10 mM MgCl2, 100 mM NaCl, 2mM dATP, 10 µM amino acid substrate and 0.1 µCi [32P] 
pyrophosphate, and were carried out at 30 °C. The reactions were initiated by addition of 
Leuorf5 to a final concentration of 50 nM. Reactions were incubated for 1 min 30 sec and 
then quenched with charcoal suspension (500 µL of 1.2% [w/v] activated charcoal, 0.1 M 
tetrasodium pyrophosphate, 0.35 M perchloric acid).The charcoal suspension was pelleted by 
centrifugation, washed twice with quenching buffer lacking charcoal and then resuspended in 
500 µL water and submitted for liquid scintillation counting. Varying concentrations of L-
proline (0.5, 1, 5, 10, 50, 100, 500 µM and 1mM) were used to measure the kinetic parameters 
of L-proline activation. For each substrate (L-proline, D-proline, L- and D-pipecolic acid, L-
glutamate and glycine) and each L-proline concentration, assays were performed in triplicate. 
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For the calculation of the kinetic parameters the ongoing radioactivity for 240 nmol [32P] 
pyrophosphate, which were applied in each assay, was measured in triplicate. Subsequently 
the average counts per minute (CPM) per nmol were calculated (the result is equivalent to z). 
After the average blank (measurements of the assay without amino acid in triplicate) was 
subtracted from the mean values of the different kinetic data points, the obtained values were 
divided through z. The obtained data is finally divided through the incubation time of the 
assay (1.5 min) and subsequently the velocity for each substrate concentration is shown in 
pmol/min. For the final Michaelis-Menten graph substrate concentration is plotted against 
velocity (pmol/min) using the SigmaBlot software. 
 
Results  
To evaluate the proposed role of Leu-orf5 (A domain) in the formation of the starter unit 
pyrrolyl-2-carboxylic acid, the gene was expressed in recombinant form and was 
biochemically characterized using an ATP-[32P]PPi exchange assay [144]. The expression 
construct was cloned into the vector pET28b+ in order to obtain a N-terminally His6-tagged 
protein. Expression was carried out in E. coli RosettaTM BL21(DE3)pLysS/RARE cells and 
recombinant Leuorf5 was then purified by nickel affinity chromatography followed by ion 
exchange chromatography (Figure 3A). Despite carrying out the procedure at 4 °C, minor 
degradation of the purified protein was observed. 
Leuorf5 is predicted to behave as a free-standing A domain, that catalyzes two half reactions. 
First L-proline is activated to L-prolyl-AMP using ATP, and then the activated aminoacyl 
moiety is transferred to the CP. The first half reaction is typically assayed by amino-acid-
dependent exchange of radioactivity from 32PPi into ATP. We first evaluated the specificity of 
this reaction using an end-point assay, with the following substrates: L-proline, D-proline, L- 
and D-pipecolic acid, L-glutamate and glycine. As shown in Figure 3B, only proline was 
activated to a significant extent in this time period (all others were < 2%). Full kinetic 
characterization further confirmed the catalytic efficiency of Leuorf5 towards L-proline 
(kcat/KM = 5.9  108 s-1M-1; Figure 3C). 
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Figure 3.  (A): SDS-PAGE analysis of the A domain (Leuorf5) (calculated molecular weight: 58.87 kDa). 
The left lane contains the molecular weight marker. (B): Relative substrate specificity determined by ATP-
[32P]PPi exchange assay catalysed by Leuorf5. Data were derived from 1.5 min end-point assays. (C): 
Kinetic characterization of Leuorf5. Shown are [substrate] vs. velocity data fit to the Michaelis-Menten 
equation, and the determined kinetic parameters. 
 
Discussion 
The scaffold of the natural product leupyrrin incorporates a pyrrole moiety which is derived 
from L-proline, and represents the starter unit of the biosynthesis. For the generation of the 
pyrrolyl-2-carboxylic acid starter unit a biosynthetic pathway was proposed that involves 
three distinct enzymes, an A domain, a CP domain and a dehydrogenase. The first enzyme of 
this pathway is the free-standing A domain (encoded by leu5) which was biochemically 
characterized in this study. Using kinetic analysis, we have shown that Leuorf5 specifically 
activates L-proline to L-prolyl-AMP by consuming ATP, demonstrating that it catalyzes the 
first half reaction in the pathway to pyrrolyl-2-carboxyl-S-PCP. Furthermore, comparison of 
the catalytic efficiency (kcat/KM) of LeuOrf5 to other L-proline activating stand-alone A-
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domains (e.g. CloN4 (1.5x106 s-1M-1) from clorobiocin biosynthesis, CouN4 (1.2x105 s-1M-1) 
from the coumermycin A1 pathway, orf11 (9.9x106 s-1M-1) from undecylprodigiosin 
biosynthesis and PltF (3.9x107 s-1M-1) from the pyoluteorin pathway) showed that Leuorf5 
(5.9  108 s-1M-1) exhibits a significant higher catalytic efficiency than the other A domains 
towards this substrate [140;141]. This effect is largely due to the low KM value (17 ± 9 M) 
measured for Leuorf5, as the determined kcat for Leuorf5 (1.00x104 ± 1.1 x103 s-1) is within 
the same range as orf11 (1.02x104 ± 4.6 x102 s-1) and PltF (1.99x104 ± 5.0 x102 s-1) [140;141].  
Biochemical studies to elucidate the remaining steps in starter unit biosynthesis were carried 
out by a diploma student, Katja Gemperlein [145], under my guidance. These experiments 
revealed that the activated amino acid is transferred to the stand-alone ACP (Leu7) and not to 
the C-PCP bidomain (Leu9), and that the subsequent desaturation reactions are catalyzed by 
the dehydrogenase homolog Leu7, as predicted. Thus, together, we have elucidated the full 
pathway to the pyrrole moiety in leupyrrin biosynthesis.  
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The origin of the uncommon extender unit in Soce thuggacin 
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Introduction 
The thuggacins were isolated from two myxobacterial species, Chondromyces crocatus Cm 
c5 and Sorangium cellulosum So ce895. The most obvious difference between the set of 
compounds in each strain is the branching functionality at C-2, a methyl in the case of the 
C.crocatus Cm c5 thuggacins versus a hexyl side chain in the case of the S. cellulosum So 
ce895 thuggacins (Figure 1A). Identification, analysis and comparison of the corresponding 
gene clusters, revealed that the final PKS modules of each assembly line are responsible for 
the structural variance at the C-2 position between Soce and Cmc thuggacins (Chapter 4). 
While the AT domain from the corresponding Cmc module accepts methylmalonyl-CoA as a 
building block, it was proposed that the corresponding Soce AT recognizes an uncommon 
extender unit.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. (A): Thuggacins produced by Sorangium cellulosum So ce895 and Chondromyces crocatus Cm 
c5. (B): Reductive decarboxylation catalysed by CCR from Rhodobacter sphaeroides [146]. 
 
Based on known pathways for the biosynthesis of other unusual extender units, several 
possibilities for the source of the extender unit were considered. For example 
hydroxymalonate, aminomalonate and methoxylmalonate are generated in a multi-step 
reaction from 1,3-bisphosphoglycerate while the intermediates are tethered to an ACP 
[59;61;147]. Subsequently the mature ACP-bound extender is recognized by the respective AT 
domain. On the other hand, the extender unit ethylmalonyl-CoA has been shown to be derived 
from a NADPH-dependent reaction catalyzed by a crotonyl-CoA reductase (CCR) [148]. These 
enzymes catalyse reductive carboxylation of unsaturated precursors to saturated products as 
illustrated for the CCR from Rhodobacter sphaeroides (Figure 1B) [148]. Consequently, we 
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considered 2-carboxy-octanoyl-CoA and 2-carboxy-octanoyl-ACP as possible candidates for 
the Soce thuggacin extender units. These building blocks could be derived from octenoyl-
CoA or octenoyl-ACP precursors which are intermediates of fatty acid degradation and 
synthesis, respectively, making them readily available in the cell.  
Detailed annotation of the gene cluster revealed one candidate enzyme to form the extender 
unit, TgaD. The gene tgaD is located at one end of the Soce thuggacin gene cluster, and 
although it shows highest homology to alcohol dehydrogenases (e.g. 46% identity, 61% 
similarity to BadC from Streptomyces roseosporus), it also exhibits convincing similarity to 
crotonyl-CoA carboxylases/reductase enzymes (CCR) (e.g. 23% identity, 40% similarity to 
the CCR of Caulobacter sp. K31). Consistent with its role in the biosynthesis, inactivation of 
tgaD in S. cellulosum So ce895 abolished thuggacin production (Chapter 4). However, to 
provide further evidence for its function as a CCR, and to discriminate between the different 
precursor substrates, TgaD was obtained in recombinant form from E. coli and characterized 
in vitro.    
 
Experimental procedures 
Cloning of pSUMOck4TgaD 
Gene tgaD was PCR amplified from cosmid DN15 (Chapter 4) using the primers 
SUMOccrfwdI (5′-acgcgGGATCCatgtacacgactgcggcttggct-3′) and SUMOccrrev (5′-     
cgagcGAATTCtcacggcgagttgacgcgata-3′).  The forward primer contains an artificial BamHI 
restriction site while the reverse primer was designed to introduce an EcoRI site downstream 
of the stop codon (restriction sites shown in bold and underlined). The PCR product was 
cloned into pJET1.2 (Fermentas), digested with BamHI and EcoRI, and subsequently ligated 
into the expression vector pSUMOck4 (pSUMO from Lifesensors modified by Carsten 
Kegler, unpublished), previously digested with BamHI and MunI. The obtained expression 
construct was designated as pSUMOck4TgaD and verified by sequencing. 
Heterologous expression and purification of TgaD 
Following several unsuccessful expression experiments with pET28b and pGEX expression 
constructs and coexpression of various chaperon systems, the expression construct 
pSUMOck4TgaD co-transformed with the chaperone plasmid pG-KJE8 (TAKARA Bio Inc.) 
into the expression strain E. coli BL21 (DE3)pLysS/RARE (Novagen) resulted in soluble 
protein expression. Expression was carried out in LB medium (3  200 mL) containing 
kanamycin sulfate (40 µg mL-1) and chloramphenicol (20 µg mL-1) at 37 °C. Chaperone 
expression was induced at the time of inoculation of the expression culture by adding 
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arabinose (2 mg mL-1) and tetracycline (5 ng mL-1). Expression of TgaD was then induced at 
A600 = 0.5–0.7 by addition of IPTG to a final concentration of 0.2 mM. After induction, the 
cells were cultivated at 16 °C over night. Cells were then harvested by centrifugation at 15344 
g at 4 °C. The cell pellet was resuspended in buffer A (20 mM Tris (pH 7.8), 200 mM NaCl, 
10% glycerol, 10 mM imidazole; 15 mL). The cells were broken by three passes through a 
French Press (1000 psi), and the insoluble material was sedimented from the lysate by 
centrifugation at 15344 g at 4 °C. The protein extract was then incubated with nickel 
sepharose (GE Healthcare; 500 µL) for 1.5 hours with slow, constant rotation at 4 °C. 
Subsequently the sepharose was centrifuged (4000 rpm, 15 min; 4 °C), the supernatant was 
discarded, and then the nickel sepharose was washed twice with 7 mL of buffer B (buffer A + 
60 mM imidazole) for 20 min. For elution of the recombinant protein, the sepharose was 
incubated for 30 min with 2.5 mL buffer C (buffer A + 500 mM imidazole) and then pelleted 
(4000 rpm, 15 min; 4 °C). The supernatant from the elution step was then analyzed by SDS-
PAGE together with the supernatants from the other purification steps. The elution fraction 
containing the recombinant protein was desalted using a PD-10 column (GE Healthcare) into 
storage buffer (50 mM Tris-HCl (pH 7.6), 1 mM EDTA, 10% glycerol, 2 mM DTT). To 
remove the SUMO-tag, the purified protein was incubated with SUMO Protease 2 (1 unit 
enzyme to 100 µg protein; LifeSensors) at 30 °C for 1 h, followed by incubation overnight at 
4 °C. Removal of the tag was followed by SDS-PAGE. The purified protein was then flash 
frozen in liquid nitrogen and stored at –80 °C.  
Synthesis of octenoyl-CoA and octanoyl-SNAC 
Synthesis of octenoyl-CoA and octanoyl-SNAC was performed by Angelika Ullrich and 
Katharina Schulz.  
Purification of octenoyl-CoA 
Crude, synthetic octenoyl-CoA was purified using the Waters autopurification system 
operating in positive ionization mode. Separation was achieved using an XBridgePrep C18 
column (Waters; 19  150 mm, 5 µm particle size, flow 25 mL min-1) with a solvent system 
consisting of solvent A (20 mM ammonium formiate (pH 6.0)) and solvent B (1:1 solvent A: 
MeOH). The following gradient was applied: 40% B for 4 min, 40–60% B over 4 min, 60–
100% B over 0.5 min, 100% B for 3 min, 100–40% B over 0.5 min, and 4 min 40% B. 
Compounds were detected by diode array and ESI-MS analysis. The purified product was 
subsequently desalted using a Sephadex column. The structure of the product was verified by 
NMR (performed by Angelika Ullrich). 
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Crotonyl-CoA reductase assay 
The reaction mixture (60 µL) contained 100 mM Tris-HCl buffer (pH 7.9), 4 mM NADPH, 
33 mM NaHCO3, 2 µg purified TgaD and 2 mM substrate. The following compounds were 
used as substrates: crotonyl-CoA, octenoyl-CoA, octanoyl-CoA, octenoyl-SNAC and octenoic 
acid. Additionally the cofactors NAD+ (1 mM), NADP+ (1 mM) and FAD+ (200 µM) with or 
without E. coli oxidoreductase (received from YanYan Li) as appropriate were added to 
assays with octanoyl-CoA as substrate. The reaction was started by adding the substrate. 
Negative controls were performed by boiling the reaction mixture for 10 min at 95 °C before 
the substrate was added. Assays were incubated overnight at 30 °C. Reactions with CoA-
esters as substrates were stopped by addition of 1% TCA, while the others were halted by 
adding 70 µL MeOH. After centrifugation, the assays were analyzed using HPLC-MS. 
Standard analysis of all assays was performed on a HPLC-DAD system (Agilent 1100) 
coupled to an HCTultra ESI-MS ion trap instrument (Brucker Daltonics) operating in positive 
ionization mode. For assays using CoA-esters as substrates, separation was achieved using a 
HydroRP column at 35 °C (Phenomenex; 150  2 mm, 4 µm particle size, flow 0.4 mL min-1), 
with a solvent system consisting of solvent A (20 mM ammonium formiate (pH 6.0)) and 
solvent B (1:1 solvent A: MeOH). The following gradient was applied: 5–100% solvent B 
over 20 min. For the other assays a Luna RP-C18 column (Phenomenex; 125  2 mm, 2.5 µm 
particle size, flow 0.4 mL min-1) was used, with a solvent system consisting of water and 
acetonitrile, both containing 0.1% formic acid. The following gradient was applied: 5–95% 
acetonitrile over 20 min. Compounds were detected in both cases by diode array and ESI-MS 
analysis. High-resolution measurements were performed on an Accela UPLC-system 
(Thermo-Fisher) coupled to an LTQ-Orbitrap (linear trap-FT-Orbitrap combination) operating 
in positive ionization mode. Compounds were separated on a BEH RP-C18 column (Waters; 
50  2 mm, 1.7 m particle size, flow 0.6 mL min-1), using a solvent system consisting of 
water and acetonitrile, both containing 0.1% formic acid. The following gradient was applied: 
5–95% acetonitrile over 9 min. The UPLC-system was coupled to the Orbitrap by a Triversa 
Nanomate (Advion), a chip-based nano-ESI interface.   
 
Results  
To demonstrate the function of TgaD in the formation of the uncommon extender unit for 
thuggacin biosynthesis, we biochemically characterized recombinant TgaD. For this, the gene 
was cloned into vector pSUMOck4 (C. Kegler, unpublished) in order to obtain an N-
terminally His6-tagged protein, and soluble expression was facilitated by coexpression of the 
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chaperones DnaK, DnaJ, GrpE, GroES and GroEL in E. coli BL21(DE3)pLysS/RARE cells 
[149;150]. The recombinant protein was then purified to homogeneity by affinity 
chromatography, and the identity of TgaD was confirmed by MALDI-MS analysis. To 
evaluate whether the SUMO tag had an effect on activity, untagged TgaD was obtained by 
proteolytic release of the tag using the recommended protease (Figure 2A). 
 
 
 
 
 
 
 
 
 
 
Figure 2. (A): SDS-PAGE analysis of the TgaD. Lane 1 contains molecular weight marker. Lane 2 shows 
the recombinant protein with attached SUMO tag (calculated molecular weight: 54.72 kDa and lane 3 
contains TgaD after cleavage of the SUMO tag (calculated molecular weight: 42.7kDa). (B): Substrates 
used in the assay: octenoyl-SNAC (1), octenoyl-CoA (2), octanoyl-CoA (3), octanoic acid (4) and crotonyl-
CoA (5). 
 
To test the capability of TgaD to catalyze reductive carboxylation, and to identify its natural 
substrate, several different substrates were tested. First of all octenoyl-CoA and octenoyl-ACP 
(Figure 6B), mimicked in the assay by octenoyl-NAC-thioester, were used in the assay. In 
addition, also octanoyl-CoA (Figure 6B) was utilized as substrate, as it could be not excluded 
that TgaD, due to its high homology to alcohol dehydrogenases, catalyzes both 
dehydrogenation and subsequent reductive carboxylation. Further substrates were crotonyl-
CoA, which was shown to be the substrate of CCR from Rhodobacter sphaeroides [148] and 
octenoic acid (Figure 6B). The recombinant protein with and without attached SUMO tag 
was incubated with the various substrates in the presence of NADPH and bicarbonate as a 
source of carbon dioxide, overnight at 30 °C. In assays with octanoyl-CoA as substrate, 
various other cofactors (NAD+, NADP+ and FAD+) were tested in combination with a 
recombinant NADH oxidoreductase from E. coli (obtained from Yanyan Li). After quenching 
the reactions, analysis was carried by HPLC-MS and high resolution LC-MS.  In assays with 
octenoyl-CoA and crotonyl-CoA as substrates, compounds with the masses m/z [M+H]+ = 
938.2 (retention time (r.t.) =17.4 min) and m/z [M+H]+ = 882.1 (r.t. = 8.8 min) respectively 
were detected, which were absent in the corresponding negative controls (the same assay 
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composition but with boiled, inactive enzyme) (Figure 3A and 3B). These masses are 
consistent with the respective carboxylated products, 2-carboxy-octanoyl-CoA and ethyl-
malonyl-CoA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. HPLC-MS analysis of different products generated by TgaD. (A): HPLC-MS analysis of 
an assay with octenoyl-CoA as substrate. The extracted ion chromatogram (EIC) of m/z [M+H]+ 
= 938.0 is shown. A compound (r.t. = 17.4 min) with the mass m/z [M+H]+ = 938.2 corresponding 
to 2-carboxy-octanoyl-CoA (6) was detected. (B): HPLC-MS analysis of an assay with crotonyl-
CoA as substrate. The EIC of m/z [M+H]+= 882 is shown. A compound (r.t. = 8.8 min) with the 
mass m/z [M+H]+ = 882.1 consistent with ethylmalonyl-CoA (7) was detected. (C): High 
resolution HPLC-MS analysis of an assay with octenoyl-SNAC as substrate. The extracted ion 
chromatogram (EIC) of m/z [M+H]+ = 290.0 is shown. A compound (r.t. = 5.4 min) with the mass 
m/z [M+H]+ = 290.1 corresponding to 2-carboxy-octanoyl-SNAC (8) was detected. 
 
Furthermore, in reactions with octenoyl-NAC thioester as substrate, a new compound with the 
accurate mass m/z [M+H]+ = 290.14209 (r.t. = 5.4 min) was identified by high resolution LC-
MS, which was not present in the appropriate negative controls (Figure 3C). The predicted 
sum formula for this compound C13H24NO4S (calcd. [M+H]+ = 290.14206, Δ = 0.1 ppm) is 
consistent with the corresponding carboxylated product, 2-carboxy-octanoyl-NAC thioester. 
In contrast, in assays that were performed with octanoyl-CoA and octenoic acid as substrates, 
no carboxylated products were observed. Assays carried out with both cleaved and uncleaved 
TgaD gave identical results (data not shown), demonstrating that the SUMO tag does not 
influence the catalytic activity of the recombinant protein. 
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Discussion 
Soce thuggacins contain an uncommon hexyl side chain at carbon C-2 that is probably 
derived from an unusual extender unit. Previous sequence analysis and inactivation 
experiments (Chapter 4) supported a possible role for TgaD in the generation of this building 
block. Here we present evidence obtained in vitro that TgaD catalyzes reductive 
carboxylation.  
As candidate substrates for TgaD, we evaluated octenoyl-CoA and octenoyl-NAC thioester, a 
simplified mimic of octenoyl-ACP. However, as the sequence analysis (Chapter 4) revealed 
that TgaD may be undergoing an evolutionary transition from a dehydrogenase to a 
reductase/carboxylase, we considered the possibility that it may also carry out 
dehydrogenation prior to reductive carboxylation. Thus, we also tested octanoyl-CoA as a 
possible substrate. Analysis by LC-MS revealed that both octenoyl-CoA and octenoyl-NAC 
thioester were reductively carboxylated by TgaD, while octanoyl-CoA was not converted to 
its carboxylated equivalent, even in the presence of various other cofactors (NAD+, NADP+ 
and FAD+) and an oxidoreductase. Furthermore, TgaD exhibited a clear preference for 
octenoyl-CoA over octenoyl-NAC thioester, as the minor 2-carboxy-octanoyl-NAC thioester 
product was only detectable by high-resolution MS. The only structural difference between 
the two substrates is the CoA moiety which absent in the NAC thioester and seems to 
contribute to substrate recognition by TgaD. However, these data alone do not allow us to rule 
out preferred use of 2-octenoyl-ACP as substrate, as it shares the phosphopantetheine arm of 
octenoyl-CoA. Consequently also ACP bound octenoyl should be tested as a substrate. 
We also explored the tolerance of TgaD to the alternative substrates octenoic acid, and 
crotonyl-CoA. A carboxylated product was not detected for octenoic acid. The reaction did 
occur, however, with crotonyl-CoA, to generate the expected ethylmalonyl-CoA. In fact, 
ethylmalonyl-CoA was produced in apparently higher yields than 2-carboxy-octanoyl-CoA as 
judged by the respective chromatograms. But if crotonyl-CoA is really a better substrate then 
octenoyl-CoA, has to be elucidated in extensive kinetic studies with both substrates.  
Taken together, these data strongly suggest that TgaD represents a new member of the family 
of CCR enzymes, which generate uncommon carboxylated extender units for PKS systems. 
Another member of this family is for example SalG from the salinosporamide synthase in the 
marine bacterium Salinispora tropica, that reductively carboxylates halogenated crotonyl-
CoA and propylmalonyl-CoA [151;152]. However, to the best of our knowledge, TgaD is the 
first enzyme to be reported which is capable of reductively carboxylating a long acyl chain.  
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Final discussion 
 
1. General summary of this work 
 
The present thesis deals with the identification and characterization of natural product 
biosynthetic pathways in myxobacteria with special focus on post-assembly line 
modifications and the biochemical analysis of specific pathway enzymes. Detailed molecular, 
bioinformatic and analytical studies were carried out in order to elucidate the biosynthesis of 
the secondary metabolites ajudazol and thuggacin in Chondromyces crocatus Cm c5 and 
thuggacin in Sorangium cellulosum So ce895. 
 
We have shown that the TE domain at the end of the ajudazol megasynthase ‘chaperones’ 
isochromanone ring formation, and is therefore a member of a novel class of TE domains. In 
addition, the involvement of two P450 enzymes in ajudazol post-assembly line modifications 
was demonstrated. One of the two P450s catalyzes a desaturation to give the ajudazol A exo-
methylene, an unusual reaction for this type of enzyme.  
 
Comparative analysis of two thuggacin clusters from different myxobacterial strains provided 
insights into the evolutionary development of biosynthetic gene clusters, and revealed the 
mechanistic basis for the structural diversity of the two thuggacin compounds. In the course of 
this study, evidence was also provided that a crotonyl-CoA-reductase homologue participates 
in the formation of the hexyl-side chain present in S. cellulosum thuggacins. Furthermore the 
different hydroxylation pattern might be due to the variable action of a FMN-dependent 
monooxygenase, whose function was proven in the case of C. crocatus by gene inactivation. 
In addition it was shown that the insertion of a strong constitutive promoter in front of the 
thuggacin gene cluster in C. crocatus, significantly increased production of the metabolites. 
 
Finally, the biochemical and catalytic characterization in vitro of selected enzymes from 
leupyrrin and disorazol biosynthesis revealed novel enzymatic transformations that contribute 
to the large structural variety of myxobacterial natural products.  
 
This section represents a summarized discussion of ajudazol and thuggacin biosynthesis, as 
the other results were already discussed in detail in Chapters 5 and 6.  
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2.  Biosynthesis of the ajudazols in C. crocatus Cm c5 
 
The highly antifungal ajudazols are generated by the myxobacterial strain Chondromyces 
crocatus Cm c5, which is known for its potential to produce secondary metabolites with 
unique structural elements. The ajudazols represent a novel class of natural products as they 
are new isochromanone derivatives that incorporate an extended side chain containing an 
oxazole ring, a Z,Z diene, and a 3-methoxybutenoic acid amide. Two derivatives of ajudazol 
have been identified to date: the major metabolite ajudazol A which incorporates an exo-
methylene functionality at C15, and ajudazol B, which instead has a methyl group at this 
position. Based on ‘retrobiosynthetic analysis’, we predicted that a mixed PKS/NRPS system 
would be responsible for ajudazol biosynthesis. The characterization of such hybrid systems is 
of particular interest, as the two different types of multienzymes have to collaborate with each 
other to construct the final product.  
Indeed, the identification and analysis of the corresponding gene cluster revealed the expected 
hybrid PKS-NRPS megasynthase. The ajudazol assembly line exhibits a high colinearity 
between the gene order, module composition and the required biosynthetic steps (Figure 1). 
The only exceptions to this colinearity are the first two modules of the biosynthesis, which are 
encoded on the last two genes (ajuK and ajuL) of the biosynthetic gene cluster. Ajudazol 
biosynthesis starts with a module containing domains for both chain initiation as well as the 
first round of chain extension. This intermixed loading module/module 1 architecture is 
frequently found in myxobacterial systems (e.g. chivosazol [69] and myxalamid [57]), and is 
also present in the two thuggacin clusters described in this thesis (Chapter 4). The remaining 
steps in the assembly of ajudazol backbones can be correlated straightforwardly to the 
modules of the subunits AjuA–AjuH, and indeed the predicted substrate specificity of the 
corresponding AT and A domains is in complete agreement with the final structure of the 
ajudazol backbone. Furthermore, the predicted complement of modifying domains is present 
in all modules with the exception of 3, 5 and 12, in which a dehydratase activity is absent due 
to a missing or inactive DH domain. It is assumed that these missing activities are 
complemented by the iterative action of DH domains in downstream modules, which was 
experimentically proven for epothilone biosynthesis [153] and afterwards postulated for several 
other myxobacterial PKS systems [69;92;154].  
The two NRPS modules that incorporate the amino acids glycine and serine respectively both 
contain modifying domains (N-MT and Ox domain) integrated into their A domains (Figure 
1).  
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Figure 1. Biosynthesis of ajudazols in C. crocatus Cm c5. The biosynthetic gene cluster and the model for 
the biosynthesis are shown. 
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Typically, modifying NRPS domains are located either downstream of the A domain as in the 
case of the N-MT domains or adjacent to the PCP, as for Ox domains [112]. In contrast, in 
myxobacterial mixed NRPS-PKS systems, these tailoring domains are often found inserted 
within the primary sequence of A domains. Additional examples of this organization include 
the N-MT domains in the tubulysin pathway [155], and the Ox domain of myxothiazol 
biosynthesis [56]. 
After the last condensation step on the ajudazol assembly line, the isochromanone ring is 
formed and the final product is released. In type I PKS-NRPS systems, type I TEs typically 
catalyze either hydrolysis to release a free acid or intramolecular cyclization to generate a 
lactone structure [94]. However, additional release mechanisms have been identified in type I 
systems. For example, the formation of the macrolactams rifampcin [156] and ansatrienin [157], 
is proposed to be catalyzed by discrete amide synthases instead of TE domains. Furthermore, 
C-terminal reductase domains were identified in biosynthetic pathways including the 
myxochelin assembly line [158-160], which are responsible for reductive release of the mature 
intermediate, resulting in aldehydes that can be reductively transaminated or further reduced 
to the alcohol [161;162]. Nonetheless, the generation of aromatic moieties during chain release is 
rare in modular type I PKS-NRPS, and instead, aromatic rings are typically produced in 
bacteria by type II or type III PKS systems, with type II systems employing cyclases and 
aromatases that direct a controlled cyclisation process [66]. Along with the chromone ring of 
stigmatellin [126] and the benzenoid ring of lasalocid [127], ajudazol represents one of the few 
examples of bacterial type I PKS-derived aromatic moieties. While the cyclization and 
aromatization reactions in stigmatellin biosynthesis are thought to be catalyzed by a novel 
type of cyclase domain located at the end of the assembly line [126], the ajudazol and the 
lasalocid assembly line terminate in TE domains, suggesting potentially new functions for 
these enzymes.  
Indeed, the present work revealed that the ajudazol TE (AjuTE) represents a novel type of TE 
involved in the formation of the isochromanone ring. Detailed sequence and phylogenetic 
analysis demonstrated that AjuTE most closely resembles type II hydrolytic TE domains 
(Figure 2). Based on this in silico analysis, we have suggested that AjuTE was once a stand-
alone type II TE domain, but was fused genetically to the end of the ajudazol assembly line. 
Due to this covalent linkage, AjuTE can no longer act as a discrete enzyme and carry out its 
proof-reading function, which normally consists in removing aberrant acyl groups from the 
carrier proteins. 
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Figure 2. Phylogenetic tree analysis of various type I and type II TEs using neighbourhood joining. 
Indicated are the type of assembly line (PKS (P), NRPS (N) or hybrid (PN)) and if the TE is a distinct 
enzyme (TEII) or part of the multienzyme complex (TEI). Uk indicates that the corresponding natural 
product is unknown. Sequence information of icumazol TEI was kindly provided by N. Luniak (N. Luniak 
unpublished). The novel class of TE identified in this work is highlighted. 
 
In support of the hypothesis of an original type II TE function, experiments in vitro with 
substrates typical for proof-reading TEIIs showed that AjuTE behaved more similarly to 
hydrolytic type I and II TEs. Nonetheless, inactivation of AjuTE by mutagenesis of the active 
site serine led to a reduction of ajudazol production, clearly indicating a role for the domain in 
formation of the isochromanone when the intermediate is bound to its active site. Thus, 
despite the fact that AjuTE may have originally functioned as a discrete type II TE, it seems 
now to play an active role in the cyclization process.  
However, the exact mechanism by which the domain catalyses ring formation remains to be 
elucidated. Initially, the full-length intermediate chain containing all functionalities required 
for ring formation is transferred to the active site serine of AjuTE. AjuTE could then direct 
the attack of the C9 hydroxyl group on the acyl ester, so that the macrolactone is generated. 
The subsequent aromatization of the second ring could then occur spontaneously (Figure 3A). 
Alternatively, the aromatic ring may be generated spontaneously, while the intermediate is 
still bound to the TE, and in the second step, AjuTE catalyzes ester bond formation between 
  Final discussion 
 
  56 
the C9 hydroxy group and the acyl ester (Figure 3B). In the third model, AjuTE simply 
provides a favourable environment that channels the tethered intermediate into a reactive 
conformation, allowing spontaneous ring formation and aromatization (Figure 3C). The 
‘chaperoning’ function of AjuTE in the third mechanism resembles the role of cyclase 
domains in type II systems [66].  
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 3. Proposed models for isochromaone ring formation. (A): TE catalyses actively 
macrolactonization and release from the assembly line. Subsequently ring I is formed spontaneously. (B): 
initially spontaneous formation of ring 1 occurs while the intermediate is still tethered to the TE. In the 
second step AjuTE catalyses formation of ring 2 and thus release of the final product. (C): AjuTE creates 
a favorable environment that allows spontaneous ring formation and aromatization.  
 
Taken together AjuTE appears to be a member of a newly-discovered class of TE domains. Its 
closest homologue, the TE domain from the jerangolid PKS cluster, exhibited a similar 
catalytic behaviour in the in vitro assays. Indeed, in its native context, JerTE would catalyze 
the formation of a six-membered ring using an internal hydroxyl nucleophile. This reaction is 
similar to the formation of ring 2 in the ajudazol isochromanone ring [163]. Further candidate 
family members are the TE domain from a cryptic PKS cluster of Gloeobacter violaceus, and 
the TE from icumazol biosynthesis, whose biosynthetic gene cluster was recently discovered 
(N. Luniak, unpublished data). While the product from the cryptic cluster has still to be 
identified, it is notable that icumazol also contains an isochromanone ring in its scaffold 
(Figure 4).  
The biosynthesis of ajudazol A and B also requires several post-PKS reactions in order to 
install the hydroxyl moiety at C8 and the C15 exo-methylene functionality of ajudazol A. The 
inactivation of the two P450 enzyme encoding genes ajuI and ajuJ in C. crocatus Cm c5 and 
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the subsequent analysis of their derivatives led to a proposal for the sequence of post-PKS 
tailoring reactions (Figure 5).  
 
 
 
 
Figure 4. Structures of the natural products ajudazol, jerangolid and icumazol A. The generation of the 6-
membered ring in jerangolid and the isochromanone ring in icumazol (according structural moieties are 
marked) probably occurs by a mechanism similar to the formation of the ajudazol isochromanone, as the 
TE domains of both assembly lines cluster together with AjuTE in the phylogenetic tree.  
 
The post-assembly modifications commence following release of deshydroxy ajudazol B from 
the assembly line. Deshydroxy ajudazol B is a substrate for both P450 enzymes, AjuJ and 
AjuI. If AjuJ acts first, the C8 position is hydroxylated, resulting in the final product ajudazol 
B. As soon as ajudazol B is generated, it is no longer recognized as a substrate by AjuI. 
Conversely, if the P450 enzyme AjuI operates first, desaturation of the C15 exo-methyl 
functionality occurs and the intermediate deshydroxy ajudazol A is produced. Deshydroxy 
ajudazol A is finally converted to ajudazol A by AjuJ, by addition of the hydroxyl group at 
C8. As the proposed mechanism excludes a conversion of ajudazol B to A and vice versa, this 
also explains the generation of the two products at a specific ratio in the natural producer C. 
crocatus. While P450-mediated hydroxylation is a common post-PKS tailoring reaction [164], 
the desaturation catalyzed by AjuJ is, to our knowledge, the first example of this reaction 
from bacterial metabolism. To date, P450-catalyzed desaturation has only been reported 
during flavone biosynthesis in plants [165], in the biosynthesis of fungal metabolites [166], and 
from eukaryotic primary metabolism [167]. 
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Figure 5. Post-assembly line modifications in ajudazol biosynthesis. The initial product released from the 
biosynthetic machinery is deshydroxy ajudazol B. Deshydroxy ajudazol B is a substrate for both P450 
enzymes AjuJ and AjuI. If AjuJ acts first, ajudazol B is produced, which is no longer recognized as a 
substrate by AjuI.  If AjuI acts first, deshydroxy ajudazol A is produced, which is subsequently 
hydroxylated by AjuJ to generate ajudazol A. 
 
     
  Final discussion 
 
  59 
3.  Thuggacin biosynthesis 
The thuggacins are macrolide antibiotics that effectively inhibit the bacterial respiratory chain 
in several Gram-positive bacteria, including clinical isolates of Mycobacterium tuberculosis, 
the causative agent of tuberculosis (TB) [34;35]. The activity against M. tuberculosis is 
particularly promising, as it represents an alternative mode-of-action relative to currently used 
TB chemotherapeutics which interact with RNA, DNA and cell wall synthesis. In addition, by 
targeting energy metabolism, both replicating and non-replicating mycobacteria are affected, 
which also represents an advantage of thuggacin over other TB drugs. Thuggacins have been 
isolated from two myxobacterial species, Chondromyces crocatus Cm c5 (Cmc-thuggacins) 
and Sorangium cellulosum So ce895 (Soce-thuggacins). The two sets of compounds show 
some structural differences. While the Soce thuggacins exhibit an uncommon hexyl-side-
chain as a C2-branching functionality, the Cmc thuggacins incorporate a methyl group at this 
position. In addition, the hydroxylation pattern differs between the sets of metabolites: Soce-
thuggacins incorporate a hydroxyl moiety at C20 which is absent in the Cmc compounds, 
while the C32 hydroxyl of Cmc-thuggacins is not present in the Soce counterparts. To 
elucidate the biosynthetic steps which are responsible for the structural differences between 
the otherwise identical compounds, the corresponding biosynthetic pathways were identified 
and analyzed. 
Both hybrid PKS-NRPS assembly lines (Figure 6), which generate the thuggacin backbone, 
contain an identical number of modules (loading module + 10 PKS modules + 1NRPS 
module) and display a high colinearity between the required biosynthetic steps and the 
complement of modules, which is uncommon for myxobacterial systems [21]. Therefore, it was 
possible to correlate small differences between the two assembly lines to the structural 
disparities between the Soce- and Cmc-thuggacins.  
The C20 hydroxyl group that is present in Soce-thuggacins but absent in Cmc-thuggacins 
arises from the divergence in catalytic steps catalyzed by modules 2 and 3 in the respective 
assembly lines. In the Cmc-cluster, modules 2 (KR and DH domains present) and 3 (KR, DH 
and ER domains present) contain all required domains that are necessary to generate the 
observed functionalities at the appropriate positions, i.e. the double bond between C21 and 
C22 and the full reduction of the β-keto group at C20. In contrast, module 2 of the Soce 
assembly line, which should also generate a double bond between C21 and C22, is missing 
the necessary KR domain and only incorporates a DH domain (Figure 6). As the DH2 domain 
cannot act without previous ketoreduction, it is likely that the intermediate is not processed 
and therefore the required double bond is not generated at this stage. However, module 3 of 
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the Soce cluster integrates a redundant DH domain, as only a KR domain is required to 
produce the observed hydroxyl moiety. Therefore, we hypothesize that the DH of module 3 
acts on the chain extension functionality generated by module 2. Thus, initially the unreduced 
intermediate generated by module 2 could be directly transferred to the ACP3 of module 3 
without undergoing chain extension, as postulated for leinamycin biosynthesis [154]. Both KR3 
and DH3 would then act on the intermediate to produce the required trans double bond. 
Afterwards, the intermediate would be passed to the upstream KS3 domain for chain 
extension. The obtained β-keto group of the tetraketide would then only be modified by the 
KR3 to yield the C20 hydroxyl moiety of Soce-thuggacin. However, the mechanism by which 
the DH3 can distinguish between the two different intermediates and dehydrate only at the 
diketide stage remains unclear. Alternatively, both domains KR3 and DH3 are used in the third 
round of chain extension and the obtained double bond is rehydrated at a later stage during the 
biosynthesis. The need for domains acting out of sequence has been observed for several other 
myxobacterial systems [92;154;168], but this is to our knowledge the first example where two 
domains show this behavior.   
The second structural difference in the backbone structure could be correlated to the final 
PKS module of each assembly line, which seems to be responsible for the alternative 
branching at C2. In silico analysis of the respective AT domains revealed that AT11 from the 
Cmc module accepts methylmalonyl-CoA as a building block, which is consistent with the 
methyl branching at C2. In contrast, no prediction could be made for Soce AT11, and it was 
assumed that this AT may recognize an uncommon extender unit. Based on known pathways 
for the biosynthesis of other unusual extender units, several possibilities for the origin of this 
extender unit were considered. It was shown for hydroxymalonate, aminomalonate and 
methoxylmalonate that these extender units are delivered as ACP-bound species to the 
appropriate AT domain [59;61;147]. Subsequently the AT domain recognizes the extender unit 
and transferred it to a CP in the assembly line. On the other hand, the extender unit 
ethylmalonyl-CoA has been shown to be derived from crotonyl-CoA. This NADPH-
dependent reaction is catalysed by a crotonyl-CoA-carboxylase (CCR), which reductively 
carboxylates crotonyl-CoA to ethylmalonyl-CoA [148]. 
The reductive carboxylation of unsaturated precursors to saturated products was initially 
shown for the CCR from Rhodobacter sphaeroides [146;148] and this novel class of 
carboxylases was recently expanded by the identification and characterization of the CCR 
SalG from Salinispora tropica [151;152]. In addition, most of the ‘normal’ extender units are 
CoA tethered, which would also argue for a CoA derived extender unit.  
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Figure 6. Biosynthetic models for thuggacin production in C. crocatus Cm c5 (A) and in S. cellulosum So 
ce895 (B). The differences in the assembly lines are highlighted.  
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Considering both possibilities, 2-carboxy-octanoyl-CoA and 2-carboxy-octanoyl-ACP were 
suggested as likely candidates for the uncommon Soce-extender unit. These extender units 
could be generated from either octenoyl-CoA or octenoyl-ACP precursors, which are 
intermediates of fatty acid degradation or synthesis, and so are continuously available in the 
cell. Analysis of the Soce gene cluster revealed one candidate enzyme which might be 
involved in the formation of the extender unit, TgaD. The gene tgaD is located upstream of 
the Soce biosynthetic gene cluster and although it shows highest homology to alcohol 
dehydrogenases, it also exhibits similarity to CCRs. Inactivation of tgaD in S. cellulosum So 
ce895 led to abolishment of thuggacin production, providing the first evidence that TgaD 
catalyzes reductive carboxylation to yield the uncommon extender unit. To confirm its role, 
and to attempt to discriminate between the different precursor substrates, TgaD was expressed 
heterologously as a N-terminal His-tagged protein and characterized in vitro. The ability of 
TgaD to catalyse reductive carboxylation was tested with several different substrates. But 
only in case of octenoyl-CoA, octenoyl-SNAC and crotonyl-CoA the respective carboxylated 
products were observed (Chapter 7). Furthermore TgaD favors octenoyl-CoA over octenoyl-
NAC thioester, whereas the latter substrate mimics 2-octenoyl-ACP. As these two substrates 
only differ in their CoA moiety this preference does not absolutely exclude 2-octenoyl-ACP 
as favoured substrate as it shares the phosphopantetheine arm of octenoyl-CoA. Taken 
together, the obtained data clearly shows that TgaD catalyses reductive decarboxylation and 
therefore represents a new member of the family of CCR enzymes, which generate 
uncommon carboxylated extender units for PKS systems. 
The last structural difference between the thuggacins is the hydroxyl group at C32 which is 
present in the Cmc-thuggacins but absent in the Soce counterparts. This hydroxyl moiety is 
added along with the shared hydroxyl group at C17, following release of the intermediates 
from the biosynthetic machinery. Despite the fact that different numbers of hydroxylations are 
observed in the two pathways, only a single candidate for catalyzing the required reactions 
was discovered in both gene clusters. TugE (Cmc) and tgaE (Soce) respectively are located 
upstream of their PKS-NRPS megasynthases, show high mutual sequence homology, and 
share a closest homologue in the public database, the FMN-dependent alkanal 
monooxygenase of Parvibaculum lavamentivorans. Inactivation of tugE in C. crocatus 
abolished Cmc-thuggacin A and C production. In place of these metabolites, we instead 
identified di-deshydroxy thuggacin (1), lacking both hydroxy groups at C17 and C32, and a 
mono-deshydroxy thuggacin. Considering the possibility that these two new derivates are 
intermediates on the pathway to the mature thuggacins, we reanalysed the wild type extract. 
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Indeed we were able to detected both compounds in the wild type and yet a second mono-
deshydroxy thuggacin. Structure elucidation of di-deshydroxy thuggacin based on high 
resolution fragmentation pattern unambiguously showed the absence of the hydroxyl groups 
at C17 and C32. However for the two mono-deshydroxy thuggacin a definitive assignment of 
the site of monohydroxylation was despite different fragmentation patterns of the derivatives 
not possible.  
The performed experiment clearly shows that Cmc TugE catalyses hydroxylation of a 
precursor thuggacin in C. crocatus and as Cmc TugE and Soce TgaA share more than 80% 
sequence identity and sequence analysis of Soce TgaA revealed no obvious evidence for 
inactivity we predict that Soce TgaA is involved in post-assembly line modification of Soce-
thuggacins. As Soce TgaA can be only responsible for the addition of the hydroxyl group at 
C17 we subsequently assume that Cmc TugE also catalyses C17 hydroxylation.   
By considering the post-assembly line modifications in S. cellulosum thuggacin biosynthesis 
in combination with the obtained data allows us to propose two possible models for the 
hydroxylations of Cmc-thuggacins. In the first model (Figure 7B) Cmc TugE carries out both 
hydroxylations. Initially it hydroxylates the position at C17 resulting in C17 mono-
hydroxylated thuggacin (2) and in the second step it adds the hydroxyl group to C32 to yield 
the mature thuggacins. The presence of minor amounts of C32 mono-hydroxylated thuggacin 
(3) in the mutant and in the wild type are probably due to an additional, promiscuous 
oxygenase encoded elsewhere in the genome. In the alternative model (Figure 7C) the 
hydroxylations are catalysed by two different enzymes. First Cmc TugE carries out C17 
hydroxylation and the subsequent C32 modification is accomplished by a second enzyme 
located at a different place in the genome. However in this model we assume that the second 
enzyme has a certain activity towards (1), which results in the generation of (3) in mutant and 
wild type. Although flavin-dependent monooxygenases are typically regiospecific [169] the 
first model requires a relaxed regiospecificity of Cmc TugE which is more reminiscent of 
P450 hydroxylases from secondary metabolism [170]. 
However, it remains unclear in the first case why the Cmc TugE homologue Soce TgaE only 
hydroxylates at C17, and does not also act at C32. One reason could be that although Soce 
TgaE and Cmc TugE are highly similar, minor differences within the active sites may only 
permit C17 hydroxylation in Soce-thuggacins. Alternatively the unique functionalities of the 
Soce-thuggacin, i.e. the hexyl-side chain and the C20 hydroxyl moiety, may only allow the 
substrate to adopt an orientation within the Soce TgaE active site which renders C17 
accessible to the catalytic machinery. If the C32 hydroxylation is instead carried out by a 
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second enzyme the lack of modification may be due to the absence of this enzyme in S. 
cellulosum.   
 
 
 
Figure 7. (A) Identified Cmc-thuggacin derivatives: all three compounds are produced by C. crocatus wild 
type, tugE- mutant generates only compound (1) and one of the two mono-deshydroxy thuggacins. (B) In 
the first hydroxylation model TugE acts twice. First it adds the hydroxyl group to C17 and subsequently 
to C32. (C) In the second model TugE just catalyse C17 hydroxylation, while the C32 modification is 
carried out by a second enzyme. 
 
Finally, comparative phylogenetic analysis of the two biosynthetic machineries allowed us to 
develop two models for the evolution of the thuggacin clusters. The phylogenetic studies were 
carried out with KS domains, as these are the most conserved domains within PKS systems 
and in general do not participate in recombinatorial exchange [171]. Therefore they are the 
domains best suited to trace the evolution of a PKS system [172]. As the thuggacin KS domains 
show highest homology to Streptomyces KSs – the first time this observation has been made 
for any myxobacterial biosynthetic pathway – it appears that a progenitor thuggacin gene 
cluster may have been acquired from a Streptomycete by horizontal gene transfer. In the first 
model a smaller ancestral thuggacin cluster present in both strains may have been differently 
expanded by module duplication to generate the present-day assembly lines. In this case the 
two thuggacins clusters represent good candidates for convergent evolution, as they appear to 
have independently developed towards a similar multienzyme organization. Alternatively the 
same full length progenitor gene cluster could have been acquired by both strains or their 
ancestors and subsequent gene conversion events coupled with deletion and exchange of 
single domains lead to the development of the present-day clusters. 
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Chapter 1: The author postulated the biosynthetic model, generated the P450 inactivation 
mutants and performed the purification of deshydroxy ajudazol A. In addition the author 
participated in the subsequent structure elucidation. Docking domain analysis was done by K. 
J. Weissman. 
 
Chapter 2: The major part of the work was performed by the author. E. Luxenburger 
performed the HPLC-MS measurements. 
 
Chapter 3: The author analysed in silico the KR domains and predicted the stereochemistry. 
 
Chapter 4: The major part of the work was performed by the author. Docking domain 
analysis was done by K. J. Weissman. HPLC-MS and high resolution measurements were 
carried out by E. Luxenburger.  
 
